Practitioner's Docket No. U 012653-9

CHAPTER II

TRANSMITTAL LETTER TO THE UNITED STATES ELECTED OFFICE (EO/US)

(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

PCT/FI98/00749

23 SEPT. 1998

23 SEPT. 1997

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE

CLAIMED

NOVEL GENE DEFECTIVE IN APECED AND ITS USE

TITLE OF INVENTION

Kai KROHN; Maarit HEINO; Part PETERSON; Hamish SCOTT; Stylianos ANTONARAKIS; Maria LALIOTI; Nobuyoshi SHIMIZU; Jan KUDOH

APPLICANT(S)

Box PCT

Assistant Commissioner for Patents

Washington D.C. 20231

ATTENTION: EO/US

NOTE: The completion of those filing requirements that can be made at a time later than 30 months from the priority date results from the Commissioner exercising his judgment under the authority granted under 35 USC 371(d). The filing receipt will show the actual date of receipt of the last item completing the entry into the national phase. See 37 C.F.R. §1.491 which states: "An international application enters the national state when the applicant has filed the documents and fees required by 35 USC 371(c) within the periods set forth in § 1.494 and § 1.495."

CERTIFICATION UNDER 37 C.F.R. 1.10*

(Express Mail label number is mandatory.) (Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date <u>MARCH 14, 2000</u>, in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number <u>EL386267956US</u>, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

JENNIFER RASHKIN

(type or print name of person mailing paper)

Signature of person mailing paper

WARNING:

Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used

to obtain a date of mailing or transmission for this correspondence.

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label

placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Transmittal Letter to the United States Elected Office (EO/US)—page 1 of 8)

WARNING:

Where the items are those which can be submitted to complete the entry of the international application into the national phase are subsequent to 30 months from the priority date the application is still considered to be in the international state and if mailing procedures are utilized to obtain a date the express mail procedure of 37 C.F.R. §1.10 must be used (since international application papers are not covered by an ordinary certificate of mailing - See 37 C.F.R. §1.8.

NOTE: Documents and fees must be clearly identified as a submission to enter the national state under 35 USC 371 otherwise the submission will be considered as being made under 35 USC 111. 37 C.F.R. § 1.494(f).

- 1. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. 371:
 - a. [x] This express request to immediately begin national examination procedures (35 U.S.C. 371(f)).
 - b. [x] The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

2.Fees

		<u> </u>										
CLAIMS FEE	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULA- TIONS							
[]*	TOTAL CLAIMS	24 - 20 =	4	x \$18.00 =	\$72.00							
	INDEPENDENT CLAIMS	4 - 3 =	1	x \$ 78.00 =	78.00							
	MULTIPLE DEPE	0										
BASIC FEE**	[] U.S. PTO AUTHOI Where an 1.482 has [] [] [X] U.S. PTO EXAMIN Where no in § 1.482 internation PTO: [] [X] []	AUTHORITY Where an International preliminary examination fee as set forth in § 1.482 has been paid on the international application to the U.S. PTO: [] and the international preliminary examination report states that the criteria of novelty, inventive step (non-obviousness) and industrial activity, as defined in PCT Article 33(2) to (4) have been satisfied for all the claims presented in the application entering the national stage (37 CFR 1.492(a)(4))										
			Total of al	oove Calculations	=\$1,120.00							
SMALL ENTITY	Reduction by ½ for (note 37 CFR 1.9, 1	must be filed.	-									
-		Total National Fee										
	Fee for recording the (See Item 13 below)											
TOTAL			То	tal Fees enclosed	\$1,120.00							

^{*}See attached Preliminary Amendment Reducing the Number of Claims.

	1.	[X]	A check in the amount of $$1,120.00$ to cover the above fees is enclosed.									
	ii.	[]	Please charge Account No in the amount of \$									
		A du _l	plicate copy of this sheet is enclosed.									
WAR	WARNING: Į		"To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date: $**(2)$ the basic national fee (see § 1.492(a)). The 30-month time limit may not be extended." 37 C.F.R. § 1.495(b)									
WARNI	NG:	submit. met with forth in months accepte comply	If the translation of the international application and/or the oath or declaration have not been submitted by the applicant within thirty (30) months from the priority date, such requirements may be met within a time period set by the Office. 37 C.F.R. § 1.495(b)(2). The payment of the surcharge set forth in § 1.492(e) is required as a condition for accepting the oath or declaration later than thirty (30) months after the priority date. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than thirty (30) months after the priority date. Failure to comply with these requirements will result in abandonment of the application. The provisions of § 1.13 apply to the period which is set. Notice of Jan. 3, 1993, 1147 O.G. 29 to 40.									
3.	[X]	A cop	y of the International application as filed (35 U.S.C. 371(c)(2)):									
NOTE:	must be Bureau 20. At the accorda the com-	filed with normally ne same ti nce with munication y need on tional fee	1.495 (b) was amended to require that the basic national fee and a copy of the international application filed with the Office by 30 months from the priority date to avoid abandonment "The International cormally provides the copy of the international application to the Office in accordance with PCT Article is same time, the International Bureau notifies applicant of the communication to the Office. In succeeding with PCT Rule 47.1, that notice shall be accepted by all designated offices as conclusive evidence the nunication has duly taken place. Thus, if the applicant desires to enter the national stage, the applicant is need only check to be sure the notice from the International Bureau has been received and then pay the tional fee by 30 months from the priority date." Notice of Jan. 7, 1993, 1147 O.G. 29 to 40, at 35-36. See below.									
	a.	[]	is transmitted herewith.									
	b.	[]	is not required, as the application was filed with the United States Receiving Office.									
	c.	[X]	has been transmitted									
		i.	[X] by the International Bureau.									
		ii.	Date of mailing of the application (from form PCT/IB/308): APRIL 1, 1999.									
		11.	[] by applicant on Date									
4.	[X]	A trans 371(c)	slation of the International application into the English language (35 U.S.C.									
	a.	[X]	is transmitted herewith.									
	b.	[]	is not required as the application was filed in English.									
	c.	[]	was previously transmitted by applicant on									
	d.	[]	will follow.									

5.	[X]	Amen U.S.C	adments to the claims of the International application under PCT Article 19 (35 . 371(c)(3)):									
NOTE:	contini this de the sub amend	The Notice of January 7, 1993 points out that 37 C.F.R. § 1.495(a) was amended to clarify the existing and continuing practice that PCT Article 19 amendments must be submitted by 30 months from the priority date and this deadline may not be extended. The Notice further advises that: "The failure to do so will not result in loss of the subject matter of the PCT Article 19 amendments. Applicant may submit that subject matter in a preliminary amendment filed under section 1.121. In many cases, filing an amendment under section 1.121 is preferable since grammatical or idiomatic errors may be corrected." 1147 O.G. 29-40, at 36.										
	a.	[]	are transmitted herewith.									
	b.	[]	have been transmitted									
		i.	[] by the International Bureau.									
			Date of mailing of the amendment (from form PCT/IB/308):									
		ii.	by applicant on									
		£373	Date									
	c.	[X]	have not been transmitted as									
		1.	[X] applicant chose not to make amendments under PCT Article 19.									
		ii.	Date of mailing of Search Report (from form PCT/ISA/210): JAN. 25, 1999. [] the time limit for the submission of amendments has not yet expired. The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.									
6.	[X]	A trans 371(c)	slation of the amendments to the claims under PCT Article 19 (38 U.S.C. (3)):									
	a.	[]	is transmitted herewith.									
	b. с.	[] [X]	is not required as the amendments were made in the English language. has not been transmitted for reasons indicated at point 5(c) above.									
7.	[X]	A copy	y of the international examination report (PCT/IPEA/409) is transmitted herewith.									
		[]	is not required as the application was filed with the United States Receiving Office.									
8.	[X]	Annex	(es) to the international preliminary examination report									
•	a.	[X]	is/are transmitted herewith.									
	b.		is/are not required as the application was filed with the United States Receiving Office.									
9.	[X] a.	A trans	slation of the annexes to the international preliminary examination report is transmitted herewith.									
	b.	[X]	is not required as the annexes are in the English language									

10. [X	【] An oa U.S.C	th or declaration of the inventor (35 U.S.C. 371(c)(4)) complying with 35									
a.	[]	was previously submitted by applicant on									
b. с.	[] i. ii.	is submitted herewith, and such oath or declaration [] is attached to the application. [] identifies the application and any amendments under PCT Article 19 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. 1.70. [X] will follow.									
Other docu	ument(s) or	information included:									
11. [X	[] An Int 17(2)([X]	ternational Search Report (PCT/ISA/210) or Declaration under PCT Article a): is transmitted herewith.									
b.	[]	has been transmitted by the International Bureau. Date of mailing (from form PCT/IB/308):									
c.	[]	is not required, as the application was searched by the United States International Searching Authority.									
d. e.	[]	will be transmitted promptly upon request. has been submitted by applicant on Date									
		Date									
12. [X a.] An Inf [X] [X] [X]	is transmitted herewith. Also transmitted herewith is/are: Form PTO-1449 (PTO/SB/08A and 08B). Copies of citations listed.									
b.	[]	will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).									
c.	[]	was previously submitted by applicant on Date									
13. []	An ass	ignment document is transmitted herewith for recording.									
		'COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING Γ APPLICATION" or [] FORM PTO 1595 is also attached.									

14.	a. b. c. d.	Additional documents: [X] Copy of request (PCT/RO/101) [X] International Publication No. WO99/15559 i. [] Specification, claims and drawing ii. [X] Front page only [X] Preliminary amendment (37 C.F.R. § 1.121) [X] Other
		Form PCT/IB/306; Form PCT/IB/308; Form PCT/IB/332
15.	[X] a. b.	The above checked items are being transmitted [X] before 30 months from any claimed priority date. [] after 30 months.
16.	[]	Certain requirements under 35 U.S.C. 371 were previously submitted by the applicant on, namely:
		AUTHORIZATION TO CHARGE ADDITIONAL FEES
WARNI	NG:	Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges if extra claims are authorized.
NOTE:	reply, re incorpor required an exten paragra construc	en request may be submitted in an application that is an authorization to treat any concurrent or future quiring a petition for an extension of time under this paragraph for its timely submission, as rating a petition for extension of time for the appropriate length of time. An authorization to charge all lees, fees under \S 1.17, or all required extension of time fees will be treated as a constructive petition for sion of time in any concurrent or future reply requiring a petition for an extension of time under this ph for its timely submission. Submission of the fee set forth in \S 1.17(a) will also be treated as a citive petition for an extension of time in any concurrent reply requiring a petition for an extension of time is paragraph for its timely submission." 37 C.F.R. \S 1.136(a)(3).
NOTE:	nor will	ts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if d, by credit to a deposit account." 37 C.F.R. § 1.26(a).
	[X]	The Commissioner is hereby authorized to charge the following additional fees that may be required by this paper and during the entire pendency of this application to Account No. $\underline{12\text{-}0425}$.
		[X] 37 C.F.R. 1.492(a)(1), (2), (3), and (4) (filing fees)
WARNI	NG:	Because failure to pay the national fee within 30 months without extension (37 C.F.R. \S 1.495(b)(2)) results in abandonment of the application, it would be best to always check the above box.
		[] 37 C.F.R. 1.492(b), (c) and (d) (presentation of extra claims)
NOTE:	Because	additional fees for excess or multiple dependent claims not paid on filing or on later presentation must

only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.492(d)), it might be best not to authorize the PTO to charge additional claim fees, except possible when dealing with amendments after final action.

- [X] 37 C.F.R. 1.17 (application processing fees)
- [X] 37 C.F.R. 1.17(a)(1)-(5)(extension fees pursuant to § 1.136(a).
- [X] 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 C.F.R. § 1.311(b).

NOTE: 37 C.F.R. 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying . . . issue fee." From the wording of 37 C.F.R. § 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

[X] 37 C.F.R. § 1.492(e) and (f) (surcharge fees for filing the declaration and/or filing an English translation of an International Application later than 30 months after the priority date).

SIGNATURE OF PRACTITIONER

Reg. No.: 25,858 Wi

Tel. No.: (212) 708-1930

Customer No.:

William R. Evans
(type or print name of practitioner)
c/o Ladas & Parry
26 West 61st Street

P.O. Address

New York, NY 10023

OF RECUPETATO 14 MAR 2000

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PCT/FI98/00749

23 SEPT. 1998

23 SEPT. 1997

INT'L APPLICATION NO.

INT'L FILING DATE

PRIORITY DATE CLAIMED

NOVEL GENE DEFECTIVE IN APECED AND ITS USE

TITLE OF INVENTION

Kai KROHN; Maarit HEINO; Part PETERSON; Hamish SCOTT; Stylianos ANTONARAKIS; Maria LALIOTI; Nobuyoshi SHIMIZU; Jan KUDOH APPLICANT(S)

Attorney Docket: U 012653-9

Commissioner of Patents and Trademarks Washington, D.C. 20231

PRELIMINARY AMENDMENT

Please amend the above application as follows.

In the Claims

Claim 3, line 1, delete "or 2"

Claim 7, line 1, delete "or 6"

Claim 8, line 1, delete "any of claims 5 to 7" and substitute therefor -- claim 5--

CERTIFICATION UNDER 37 C.F.R. 1.10*

(Express Mail label number is mandatory.) (Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date <u>MARCH 14, 2000</u> in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number <u>EL386267956US</u>, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

JENNIFER RASHKIN

(type or print name of person mailing paper)

Ignature of person mailing paper

WARNING:

Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

Claim 11, line 1, delete "or 10"

Claim 13, line 1, delete "any one of claims 9 to 12" and substitute therefore --claim 9--

Claim 14, line 1, delete "any one of claims 9 to 14" and substitute therefor --claim 9--

3/11/00

Claim 15, line 1, delete "any one of claims 9 to 14" and substitute therefor --claim 9--

Claim 18, line 1, delete "or 17"

Claim 19, lines 1-2, delete "any one of claims 1 to 4" and substitute therefor --claim 1--

Claim 20, line 1, delete "any one of claims 5 to 7" and substitute therefor --claim 5--

Claim 21, lines 1-2, delete "any one of claims 1 to 4" and substitute therefor --claim 1--

Claim 22, lines 1-2, delete "any one of claims 1 to 4" and substitute therefor --claim 1--

23. (amended) Reagents reacting with the DNA sequence characterized by comprising the sequence id. no. 1 or a functional fragment or variant thereof encoding a protein having the same functional activity, or an functionally equivalent isolated DNA sequence hybridizable thereto or the protein of claim 5 or with reagents therewith.

Respectfully submitted,

William R. Evans c/o Ladas & Parry 26 West 61st Street New York, NY 10023

Reg. No. 25,858 (212) 708-1930

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) & 1.27(c))—SMALL BUSINESS CONCERN Docket Number (Optional)
Applicant or Patentee:Finnish Immunotechnology itd Serial or Patent No.:
Filet or Issued: Title: Novel gene defective in apeced and its use
I hereby declare that I am
the owner of the small business concern identified below. an official of the small business concern empowered to act on behalf of the concern identified below:
NAME OF SMALL BUSINESS CONCERN Finnish Immunotechnology Ltd. ADDRESS OF SMALL BUSINESS CONCERN Lenkkellijänkatu 8, FIN-33530 Tampere, Finland
I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12. and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control both.
I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:
the specification filed herewith with title at listed above. the application identified above. the patent identified above.
If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention must file separate verified statements averting to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). Each person, concern or organization having any rights in the invention is listed below:
no such person, concern or organization exists. each such person, concern or organization is listed below.
Separate verified statements are required from each named person, concern or organization having rights to the invention averting to their status as small entities, (37 CFR 1-27)
I acknowledge the duty to file, in this application or patent notification of any change in status resulting in loss of emittlement to small entity status prior to paying, or at the time of paying, the explication that is not fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 CFR 1.28(b))
Thereby declars that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these matements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may propardize the validity of the application, any patent insuing thereon, or any patent to which this verified statement is directed.
NAME OF PERSON SIGNING Pekka Sillanaukee
TITLE OF PERSON IF OTHER THAN OWNER _ chief executive officer
ADDRESS OF PERSON SIGNING Lenkkeilijänkatu 8, 33520 TAMPERE FINLAND
DATE March 7th, 2000

PTO/SB/10 (11-90)

Peters and Trademark Office U.S. DEPARTMENT OF COMMERCE

09/5 08/58 12 Rec'd P01/P10 1 4 MAR 2000

1

NOVEL GENE DEFECTIVE IN APECED AND ITS USE

Field of the invention

The present invention relates to a novel gene, a novel protein encoded by said gene, a mutated form of the gene and to diagnostic and therapeutic uses of the gene or a mutated form thereof. More specifically, the present invention relates to a novel gene defective in autoimmune polyendocrinopathy syndrome type I (APS I), also called autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) (MIM No. 240,300).

10 Background

Autoimmune polyglandular syndrome type I (APS I), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare recessively inherited disease (MIM No. 240,300) that is more prevalent among certain isolated populations, such as Finnish, Sardinian and Iranian Jewish populations. The incidence of the disease among the Finns and the Iranian Jews is estimated to be 1:25000 and 1:9000, respectively, whereas only few cases in other parts of the world are found each year.

APECED is one of the two major autoimmune polyendocrinopathy syndromes. The causing factor of APECED has not yet been identified. The 20 syndrome is characterized by lack of tolerance to numerous self-antigens and can therefore be considered as a prototype of organ-specific autoimmune diseases. In APECED, the patient develops chronic mucocutaneous candidiasis soon after birth, and later several organ-specific autoimmune diseases, mainly hypoparathyreoidism, Addison's disease, chronic atrophic gastritis with 25 or without pernicious anemia, and in puberty gonadal dysfunction occur [Ahonen P, Clin. Genet. 27 (1985) 535-542]. An accepted criterion for diagnosis of APECED is the presence of at least two of the three main symptoms, Addison's disease, hypoparathyroidism and candidiasis, in patients [Neufeld, M. et al., Medicine 60 (1981) 355-362]. Immunologically, the major 30 findings are the presence of high-titer serum autoantibodies against the effected organs, antibodies against Candida albicans, and low or lacking T-cell responses toward candidal antigens [Blizzard, R. M. and Kyle M., J. Clin. Invest. 42 (1963) 1653-1660; Arulanantham, K. et al., New Eng. J. Med. 300 (1979) 164-168; Krohn, K. et al., Lancet 339 (1992) 770-773; Uibo R. et al., J. 35 Clin. Endocrinol. Metab. 78 (1994) 323-328]. The disease usually occurs in

35

childhood, but new tissue specific symptoms may appear throughout life [Ahonen, P. et al., New Engl. J. Med. 322 (1990) 1829-1836]. APECED is not associated with a particular HLA haplotype, and both males and females are equally affected consistant with the autosomal recessive mode of inheritance.

The locus for the APECED gene has been mapped to chromosome 21q22.3 between gene markers D21S49 and D21S171 based on linkage analysis of Finnish families [Aaltonen, J. et al., Nature Genet. 8 (1994) 83-87]. Recently, Börses et al. reported a maximum LOD score of 10.23 with marker D21S1912 just proximal to the gene PFKL, and thus by linkage disequilibrium 10 studies the critical region for APECED can be considered to be less than 500 kb between markers D21S1912 and D21S171. Locus heterogeneity was not revealed by linkage analysis of non-Finnish families [Björses, P. et al., Am. J. Hum. Genet. 59 (1996) 879-886].

For the APECED gene, the name "autoimmune regulator" or "AIRE" 15 has been adopted by the scientific community after the priority date of the present application. Similarly the protein encoded by the AIRE gene is now called the "AIRE protein".

Physical maps of human chromosome 21g22.3 have been developed using YACs, and bacterial based large insert cloning vectors 20 [Chumakov et al., Nature <u>359</u> (1992) 380; Stone et al., Genome Res. <u>6</u> (1996) 218], and many laboratories have contributed to the construction of a transcription map of the whole chromosome and 21q22.3 in particular [Chen et al., Genome Res. 6 (1996) 747-760; Yaspo et al., Hum. Mol. Genet. 4 (1995) 1291-1304]. Numerous trapped exons from chromosome 21 specific cosmids 25 and also physical contigs from the APECED critical region have been identified and partially characterized. In addition, a number of ESTs from the international human genome project have been mapped to the APECED critical region.

Recently, as part of the international efforts of generating the entire 30 sequence of human chromosome 21 and international agreements on the immediate availability of this type of sequence data, the partial sequence of the APECED gene critical region was made available in GenBank by the Stanford Human Genome Center which is currently carrying out the sequencing of 1.0 Mb around the critical region of the APECED gene.

However, the precise location and the sequence of the APECED gene and the nature of the gene product have not so far been clarified. Thus

at present the diagnosis of APECED is based mainly on developed clinical symptoms and typical clinical findings, e.g. the presence of autoantibodies against adrenal cortex or steroidogenic enzymes P450c17 and/or P450scc. The linkage analysis is seldom used. Further, means for natal or presymptomatic diagnosis of the disease are not easily available, since the linkage analysis provides only an indirect data through known gene markers and requires samples from several family members in several generations. Additionally, the linkage analysis is tedious and can be performed only in specialized laboratories by highly-skilled personnel.

Also the mapping of the carriers of the disease gene is presently based on the linkage analysis and thus not readily available.

Summary of the invention

We have now identified a novel gene encoding a novel zinc finger protein, designated as autoimmune regulator 1 or AIR-1, which is mutated in APECED. The novel gene and protein allow further development of the diagnosis and therapy of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

The object of the invention is to provide means which are useful in a diagnostic method and a gene therapeutic method in the diagnosis and treat-20 ment of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

Another object of the invention is to provide a novel method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED, including the pre- and postnatal diagnosis and the mapping of the carriers, the method being easy and reliable to perform.

The present invention relates to an isolated DNA sequence comprising the sequence id. no. 1 or a functional fragment or variant thereof, or a functionally equivalent isolated DNA sequence hybridizable thereto, the DNA sequence being associated with diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED. Preferably said isolated DNA sequence includes a gene defect responsible for APECED.

The present invention also relates to a protein comprising the amino acid sequence id. no. 2 or a functionally equivalent fragment or variant thereof, the protein being associated with diseases related to immune maturation and

regulation of immune response towards self and nonself, such as APECED. Said protein has distinct structural motifs, including the PHD finger motif (PHD), the LXXLL motif (L), proline-rich region (PRR), and cystein-rich region (CRR).

The present invention further relates to a method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED, comprising detecting in a biological specimen the presence of a DNA sequence comprising the sequence id. no. 1 or a functional fragment or variant thereof, or a functionally 10 equivalent DNA-sequence hybridizable thereto, the DNA sequence being associated with diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

The present invention further relates to the use of the aboveidentified DNA-sequences in the diagnosis of diseases related to immune 15 maturation and regulation of immune response towards self and nonself, such as APECED.

The present invention further relates to a method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED, comprising detecting in a 20 biological specimen the presence or the absence of a protein comprising the sequence id. no. 2 or a functionally equivalent fragment thereof, the protein being associated with diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

The present invention further relates to the use of the above-25 identified protein or a functionally equivalent fragment thereof in the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

The present invention further relates to the use of the aboveidentified DNA sequences in gene therapy or for the preparation of a 30 pharmaceutical preparation useful in a gene therapy method of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

Brief description of the drawings

Figure 1 shows a physical map of the APECED gene locus in the 35 chromosome 21g22.3. Cosmids D1G8, D40G11, D9G11, D28B11, and D4G11, overlapping clones used for the genomic sequencing [Kudoh, J. et al.,

DNA Res. 4 (1997) 45 -52] are indicated by horizontal lines. The APECED gene located just proximal to the 5' end of the neighboring gene PFKL is indicated by a solid arrow. N indicates Notl sites. DNA marker D21S1912 is shown as open box.

Figure 2 shows the structures of the APECED gene and AIR proteins. (A) Cloning strategy of APECED cDNAs and the order of the exons in the APECED gene. DNA fragments amplified by PCR and 3'- and 5'-RACE are indicated by the lines. Exon 1' is the 5'-noncoding exon of the AIR-2 and AIR-3. An additional alternative splicing of AIR-3 in exon 10, resulting in an 10 amino acid change in its downstream, is indicated by vertical lines. Each exon, except exon 1', is bordered by the common splice site consensus sequence, ag:gt. Mutations in the exon 2 and exon 6 are indicated by the arrows. (B) Schematic presentation of the three AIR proteins showing distinct structural motifs, including the PHD finger motif (PHD), the LXXLL motif (L), proline-rich region (PRR), and cystein-rich region (CRR).

Figure 3 shows electropherograms showing the sequence surrounding the mutations in the APECED gene. (A) Mutation analysis of a Swiss APECED family. The parents are heterozygous for the allele (normal "C" and abnormal "T"). The affected boy and girl show the "C" to "T" transition 20 resulting in the "Arg" to "Stop" nonsense mutation at amino acid position 257. (B) Mutation analysis of two Finnish APECED patients. The patient MP is homozygous for the mutant allele (left), NP is heterozygous for the allele (right). (C) The patient NP shows the "A" to "G" transversion resulting in the "Lys" to "Glu" missense mutation at amino acid position 42. FLEB is a normal 25 control.

Figure 4 shows the result of a restriction enzyme Tagl digestion assay demonstrating the R257stop mutation. Four APECED patients [HP1 (lane 1), HP2 (lane 2), NP (lane 6), and MP (lane 8)], the mothers of two families [HM (lane 5) and NM (lane 7)], two healthy siblings [HN1 (lane 3) and HN2 (lane 4)] of family H and normal controls [C1, C2 and C3 (lanes 9-11)] are shown. The APECED patients HP1, HP2 and MP are homozygotes for the R257stop mutation. The APECED patient NP is heterozygous for the R257stop mutation but is carrying a mutation at a different position in another allele of the APECED gene (shown above in Fig. 3C). Both mothers (HM and 35 NM) and two healthy siblings (HN1 and HN2) are heterozygous for the R257stop mutation and therefore carriers of APECED but are not having the

10

30

disease. Two controls (C1 and C2) are both homozygous for normal alleles. Normal alleles produce a lower 225 bp fragment, the mutated fragment is upper band at 285 bp.

Figure 5 shows an amino acid sequence alignment for the PHD 5 finger motif of AIR-1, Mi-2, and TIF1. The consensus amino acid residues conserved in the PHD finger motif is indicated by the bold letters underneath. The residues that are identical with AIR-1 (aa 299-340) are shown by the dots. GenBank accession nos. of Mi-2 and TIF1 are X86691 and AF009353, respectively.

Figure 6 is a Western blot showing the expression of AIR-1 in fetal liver. A sample of fetal liver was run on PAGE, transferred to a nitrocellulose filter and probed with sera as follows: Lane 1, control mouse serum, lane 2, control mouse serum absorbed with peptide AIR-1/2 (sequence id. no. 25), lanes 3 and 4, serum from a mouse immunized with peptide AIR-1/2 for four and six weeks, respectively and absorbed with peptide AIR-1/2, lanes 5 and 6, unabsorbed serum from a mouse immunized with peptide AIR-1/2 for four and six weeks, respectively. The strong band seen in lanes 5 and 6 represent the AIR-1 protein with a molecular weight of approx. 58 kD, the lower band is an approx. 20 kD breakdown product of the AIR protein. The bands seen in all 20 lanes are non-specific.

Figure 7 shows the expression of the APECED mRNA (7A) or the AIR protein (7B, 7C and 7D) demonstrated by in situ hybridization (7A) or by immunohistochemistry (7B, 7C and 7D). Figure 7A shows APECED mRNA positive cells scattered in the medullary region of human thymus. Figure 7B 25 shows similar cells with the same localization now stained for the AIR protein. Figure 7C is a higher magnification of 7B, showing the localization of the AIR protein in the nuclei. Note the speckled localiation pattern in the nuclei. Figure 7D shows the cytoplasmic localization of the AIR protein in a few cells in lymph node medulia.

Figure 8 shows the phenotypic characterization of the APECED reactive cells in thymus by double-immunofluorescence. The AIR protein is seen as red colour in the nuclei, forming typical speckled pattern with nuclear dots. In Figure 8A, the co-staining is with an antibody recognizing low molecular weight markers (AE1). The APECED positive cells fall into two 35 types, one is expressing cytokeratin and is thus epithelial cell, the other one is non-epithelial and do not co-express cytokeratins. In Figure 8B an APECED

positive cell co-epresses a marker (CD83) typical for cells belonging to monocyte-macrophage-dendritic cell lineage.

Figure 9 shows the expression of the AIR protein, demonstrated by immunofluorescence, in mature, activated dendritic cells from peripheral blood.

The expression of the AIR protein shows as distinct dots in the nuclei of dendritic cells.

Detailed description of the invention

The present invention is based on studies aiming for the identification and characterization of the gene defect in APECED. In the sequence studies, a cosmid/BAC (bacterial artificial chromosome) contig of 520 kb covering four gene markers D21S1460-D21S1912-PFKL-D21S154 [Kudoh, J. et al., DNA Res. 4 (1997) 45-52] was constructed, and genomic sequencing in this region was performed [Kawasaki, K. et al., Genome Res. 7 (1997) 250-261]. From this genomic sequence information the distance between D21S1912 and PFKL was determined to be approximately 140 kb (Fig. 1).

Using a computer program, such as GRAIL and GENSCAN [Uberbacher, E. C. and Mural, R. J., Proc. Natl. Acad. Sci. USA <u>88</u> (1991) 11261-11265; Burge, C. and Karlin, S., J. Mol. Biol. <u>268</u> (1997) 78-94], gene screening in the partial sequencing data within this region was performed. GENSCAN predicted several genes between D21S1912 and PFKL. One of these genes located just proximal to the PFKL gene contained the previously trapped exon HC21EXc33 [Kudoh, J. *et al.*, DNA Res. <u>4</u> (1997) 45-52] or MDC04M06 [Chen, H. *et al.*, Genome Res. <u>6</u> (1996) 747-760]. A set of primers for polymerase chain reaction (PCR) was then designed from the predicted exons. The PCR screening of various cDNA libraries using these primers allowed the isolation of a cDNA clone containing the exon HC21EXc33 (exon 13) from the thymus cDNA library (Fig. 2A).

A 3'-rapid amplification of cDNA ends (3'-RACE) and 5'-RACE using Marathon TM cDNA Amplification Kit (Clontech Laboratories Inc, California, USA) according to manufacturer's protocol from the thymus cDNA library was performed using a primer c33F (sequence id. no. 7) and a primer 1R (sequence id. no. 8), respectively.

Sequencing analysis revealed a unique sequence of 2027 bp in overlapping PCR products that contains a 1635-bp open reading frame (ORF) from methionine at nt 128 to a TAG stop codon at nt 1763 encoding a predic-

ted novel protein designated AIR-1, for autoimmune regulator 1. AIR-1 encodes a protein of 545 amino acids with a predicted isoelectric point of 7.32 and a calculated molecular mass of 57,723 (Fig. 2B).

A 5'-RACE from the thymus cDNA using a primer 4R (sequence id. 5 no. 9) resulted in an alternatively spliced product. Furthermore, two types of the cDNA clones were amplified with a primer pair 3F/c33R (sequence id. no. 10/sequence id. no. 11) and these clones encode for AIR-2 and AIR-3 proteins, sequence id. no. 4 and sequence id. no. 6, respectively (Fig. 2A) (sequence id. no. 3 and sequence id. no. 5). The AIR-2 and AIR-3 proteins 10 consist of 348 and 254 amino acids, respectively (Fig. 2B). These results suggest that the APECED gene is transcribed as at least three types of mRNA by alternative splicing and/or use of an alternative 5' exon within the gene. RT-PCR analysis [Griffin, H. G. and Griffin, A. M., PCR Technology. Current Innovations, CRC Press, 1994] revealed that the AIR-1 transcript is also ex-15 pressed in fetal liver (data not shown).

The APECED gene is approximately 13-kb in length and contains 15 exons, including the exon 1' specific to AIR-2 and AIR-3. It is transcribed in the direction of centromere to telomere (Figs 1, 2A). Based on this information, PCR primers were designed to amplify each exon from the genomic DNA and a mutation analysis of Swiss and Finnish APECED families was performed. Sequence comparison identified two mutations in the APECED gene of the patients (Fig. 3). The first mutation changes an Arg codon (CGA) to a stop codon (TGA) at amino acid position 257 in exon 6. This mutation was designated as R257stop mutation. The second mutation is a missense muta-25 tion that derived from the maternal chromosome in one Finnish patient (NP): a Lys codon (AAG) changes to a Glu codon (GAG) at amino acid position 42 in exon 2. This mutation is designated as K42E mutation (Figs 2A, 3C).

The R257stop mutation destroys a Taql restriction enzyme site and the K42E mutation introduces a novel Taql site. Thus these two mutations can 30 be easily demonstrated in one or both alleles by Taql digestion or by digestion using another enzyme cleaving at the recognition site 5'-TCGA-3'(Fig. 4).

The AIR-1 protein has strong homology in certain domains to the major autoantigens (Mi-2) associated with the autoimmune disease dermatomyositis [Seeig, H. P. et al., Arthritis Rheum. 38 (1995) 1389-1399; 35 Ge, Q. et al., J. Clin. Invest. 96 (1995) 1730-1737], Sp140, a protein from the nuclear body, an organelle involved in the pathogenesis of certain types of

leukemia, and which is also the target of antibodies in the serum of patients with the autoimmune disease primary bilary cirrhosis [Bloch, D. B. et al., J. Biol. Chem. 271 (1996) 29198-29204]. In addition, the homologies extend to other nuclear proteins such as TIF1 [Le Douarin, B. et al., EMBO J. 14 (1995) 2020-2033]. LYSP100 [Dent, A. L. et al., Blood 88 (1996) 1423-1426], and putative yeast and C. elegans proteins. The AIR-1 protein homologies are principally in two PHD finger motifs (amino acid 299 to 340 and 434 to 475) (Fig. 5). AIR-1 also contains a proline-rich region (amino acid 350 to 430) (Fig. 2B). The PHD finger is a cysteine-rich structure that is distinguished from the 10 RING finger (C3HC4) and LIM domain (C2HC5) because it contains a consensus of C4HC3. [Aasland, R. et al., Trends Biochem. Sci. 20 (1995) 56-59]. The PHD finger motif is found in a number of chromatin-associated proteins such as HRX that is involved in the t(11:17) translocation in acute leukemia [Chaplin, T. et al., Blood 86 (1995) 2073-2076]. The proline-rich region is 15 assumed to be involved in protein-protein interaction or DNA binding. The presence of the PHD finger and proline-rich regions indicates a function for AIRs as transcription regulatory proteins. However, the AIR proteins have no apparent nuclear translocation signal, and thus other proteins containing such signal may interact with AIR to translocate it to the nucleus. In fact, the AIR 20 proteins also have the LXXLL motif that is a signature sequence to bind to nuclear receptors [Heery, D. M. et al., Nature 387 (1997) 733-736] (Fig. 2B).

The clinical picture of APECED and the observed immunological abnormality with strong autoimmune response towards several target organs and antigens suggest that the product of the APECED gene has a central role in immune (ontogeny) maturation and regulation of immune response towards self and nonself.

According to the diagnostic method of the invention, the presence of the defective APECED gene can be detected from a biological sample by any known detection method suitable for detecting mutations. Such methods include the method described by Saiki *et al.* [Proc. Natl. Acad. Sci USA <u>86</u> (1989) 6230-6234) utilizing hybridization to an allele specific oligonucleotide probe, or modifications thereof; the method described by Newton, C. R. *et al.* [Nucl. Acids Res. <u>17</u> (1989) 2503-2516] using the DNA sequences or DNA-fragments of the invention as probes; the solid phase minisequencing method described by Syvänen *et al.* [Genomics <u>8</u> (1990) 684-692] in which use is made of a biotinylated probe; or the oligonucleotide ligation method described

by Landegren, U. et al. [Science 241 (1988) 1077-1080]. Methods include the denaturing gradient gel electrophoresis (DGGE) [Fischer, S.G. and Lerman, L.S., PNAS 80 (1983) 1579-1583] or a modification of this method, constant denaturant gel electrophoresis (CDGE) [Hoving et al., Genes Chromosomes Cancer 5 (1992) 97-103]. The mutation separation principle of DGGE and CDGE is based on the melting behavior of the DNA double helix of a given fragment.

Since the mutations of the APECED gene involve a site sensitive to *Taq*I digestion, the mutation are preferably detected in one or both alleles by 10 *Taq*I digestion or by digestion using another enzyme cleaving at recognition site 5'-TCGA-3' The chemical mismatch cleavage for mutation analysis can be used [Grompe, M. *et al.*, Proc. Natl. Acad. Sci. USA <u>86</u>(15)(1989) 5888-5892].

In the diagnostic method of the invention the biological sample can be any tissue or body fluid containing cells, such as blood, e.g. umbilical cord blood, separated blood cells, such as lymphocytes, B-cells, T-cells etc., biopsy material, such as fetal liver or thymus biopsy, sperm, saliva, etc. The biological sample can be, where necessary, pretreated in a suitable manner known to those skilled in the art.

When the DNA sequence of the present invention is used 20 therapeutically any techniques presently available for gene therapy can be employed. Accordingly, in the technique known as ex vivo therapy patient cells (e.g. umbilical cord blood from the fetus) with the defective gene are taken from the patient, DNA sequences encoding the normal (healthy) gene product incorporated in a carrier vector are transducted or transfected to the cells and 25 the cells are returned to the patient. If the techniques known as in situ therapy is used, the DNA sequences encoding the normal gene product are first inserted to a suitable carrier vector, and the carrier is then introduced to the affected tissue, such as peripheral blood, liver or bone marrow. The carrier vector used can be a retrovirus vector, an adeno virus vector, an adeno 30 associated virus (AAV) vector or an eucaryotic vector. The therapy can be performed intra utero or during adult life. Depending on the cells to be treated these techniques lead either to a transient cure, where cells from affected organ are treated, or to a permanent cure, in case of the treatment of stem cells.

The present invention provides means for an easy and more rapid diagnosis of the diseases related to immune maturation and regulation of

immune response towards self and nonself, such as APECED, and, specifically, enables prenatal diagnosis and carrier diagnosis. Furthermore, it provides a background for therapy.

The invention is now elucidated by the following non-limiting 5 examples.

Example 1

Localization of the APECED gene

Genomic sequencing of cosmid DNAs was performed by the shotgun method described by Kawasaki, K. et al., Genome Res. 7 (1997) 250-261. Cosmids D1G8, D40G11, D9G11, D28B11, and D4G11 and gene marker D21S1912 are described by Kudoh, J. et al., DNA Res. 4 (1997) 45-52].

cDNA cloning

The phage DNAs prepared from human thymus cDNA library (Clontech, HL1127a) were used as a PCR template. 20 ng of phage DNA which represents approximately 4x10⁸ phages was added to a 10 ml of reaction mixture containing 1x buffer [16mM (NH₄)₂SO₄, 50mM Tris-HCl, pH 9.2, 1.75 mM MgCl₂, 0.001% (w/v) gelatin), 0.2 mM each of dNTPs, 1M Betaine (Sigma), 0.35 U of Tap and Pwo DNA polymerase (EXpand Long Template PCR System, Boehringer Mannheim), and 0.5 mM of each of the primers, 2F and c33R, 2F and 4R, and 2F' and 2R', respectively.

The cDNA fragment was amplified by PCR using the following conditions: 94°C for 3 min., 35 cycles of 94°C for 30 sec, 60 °C for 30 sec in 2F/c33R and 2F/4R or 65°C for 30 sec in 2F'/2R', and 68°C for 90 sec. 3'- and 5'-RACE were carried out by Marathon cDNA Amplification Kit (Human Thymus; Clontech). PCR reaction was performed in a 10 μl volume containing 1x buffer (50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl₂, 0.001% (w/v) gelatin), 0.2 mM each of dNTPs, 0.25 U of AmpliTaq Gold polymerase (Perkin-Elmer), and 0.5 mM of each of the exon-specific primers. 3'-RACE product was amplified by PCR with the following conditions: 95°C for 9 min., 35 cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec.

The cDNA fragments were sequenced by the dye deoxy terminator cycle sequencing method (according to ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit protocol P/N 402078, Perkin Elmer Corporation, California) using specific primers, 2F and c33R, and AmpliTaq/FS

DNA polymerase (Perkin-Elmer), and then analyzed by using an automatic DNA sequencer (Applied Biosystems 377). Primer sequences used were

1R: 5'-GTTCCCGAGTGGAAGGCGCTGC-3' (sequence id. no. 8)

2F: 5'-GGATTCAGACCATGTCAGCTTCA-3' (sequence id. no. 12)

3F: 5'-GAGTTCAGGTACCCAGAGATGCTG-3' (sequence id. no.

10)

5

10

30

c33R: 5'-CTCGCTCAGAAGGGACTCCA-3' (sequence id. no. 11)

4R: 5'-AGGGGACAGGCAGGCCAGGT-3' (sequence id. no. 9)

2F': 5'-GTGCTGTTCAAGGACTACAAC-3' (sequence id. no. 13)

2R': 5'-TGGATGAGGATCCCCTCCACG-3' (sequence id. no. 14)

AP1: 5'-CCATCCTAATACGACTCACTATAGGGC-3' (sequence id.

no. 15) and

c33F: 5'-GATGACACTGCCAGTCACGA-3' (sequence id. no. 7).

Example 2

15 Mutation analysis of the APECED gene

For the mutation analysis the DNA samples were purified from periferal blood mononuclear cells from patients with APECED and from suspected carriers of APECED and from normal healthy controls (according to Sambrook *et al.* 1989, Molecular Cloning. A Laboratory Manual. CSH Press) and subjected to PCR using primers specific for all identified exons.

For sequencing the mutated exons, PCR fragments, 6F/6R in exon 6 and 49300F/49622R in exon 2, were amplified by PCR with the following conditions: 95°C for 9 min., 35 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec, and 94°C for 3 min., 35 cycles of 94°C for 30 sec, 60°C for 30 sec, and 68°C for 30 sec, respectively. The PCR products were sequenced using specific primers

6F: 5'-TGCAGGCTGTGGGAACTCCA-3' (sequence id. no. 16)

6R: 5'-AGAAAAAGAGCTGTACCCTGTG-3' (sequence id. no. 17)

3R: 5'-TGCAAGGAAGAGGGGCGTCAGC-3' (sequence id. no. 18)

49300F: 5'-TCCACCACAAGCCGAGGAGAT-3' (sequence id. no.

19) and 49622R: 5'-ACGGGCTCCTCAAACACCACT-3' (sequence id. no. 20).

In the mutation analysis by sequencing, two Swiss and three Finnish (HP1, HP2 and MP) patients with APECED were homozygous for R257stop allele, whereas one Finnish patient (NP) was heterozygous for this mutation (Fig. 3A, B). The R257stop mutation of NP was derived from the

paternal chromosome. The second mutation, K42E mutation, was found in one Finnish patient (NP): a Lys codon (AAG) changes to a Glu codon (GAG) at amino acid position 42 in exon 2.(Figs 2A, 3C). This mutation derived from the maternal chromosome.

5 Example 3

Restriction enzyme Taql analysis of two mutations in exons 2 and 6 of APECED gene

Analysis of the mutation sites in exons 2 and 6 in large series of individuals was performed using the restriction enzyme Taql.The Taql digestion for exons 2 and 6 was done as follows. Ten microlitres of amplification product was incubated at 65°C for 1 hour in 20 µl of reaction mixture containing 1x Taql digestion buffer (New England Biolabs, NY, 100 µl/ml of BSA and 10U of Taql enzyme (New England Biolabs, NY). After the digestion fragments were separated in 1.5% agarose gel and visualized by 15 EtBr staining.

For exon 2, the fragment containing the mutation site K42E was amplified with primers GR1/2F and GR1/2R with the following conditions: 95°C for 3 min., 35 cycles of 94°C for 30 sec, 62°C for 30 sec and 72°C for 1 min. The 1x reaction mix used contained 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 20 mM MgCl₂, 0.001% (w/v) gelatin), 0.2 mM each of dNTPs, 0.25 U of Dynazyme (Finnzymes, Finland), and 0.5 mM of each of the exon-specific primers. The normal allele produces a 312 bp fragment whereas the mutated allele gives a 133 bp and a 179 bp fragment. Primer sequences for GR1/2F and GR1/2R are 5'-TGGAGATGGGCAGGCCGCAGGGTG (sequence id. no. 21) and 5'-CAGTCCAGCTGGGCTGAGCAGGTG (sequence id. no. 22), respectively.

For exon 6, the fragment containing the R257stop mutation site was amplified with primers GR1/5IF and GR1/5IR with the same conditions described for exon 2 (see above). The normal allele produces a 225 bp fragment whereas the mutated allele gives a 285 bp fragment. Primer sequences for GR1/5IF and GR1/5IR are 5'-GCGGCTCCAAGAAGTGCATCCAGG (sequence id. no. 23) and 5'-CTCCACCCTGCAAGGAAGAGGGGC (sequence id. no. 24), respectively.

The screening of 50 Finnish and 50 Swiss healthy individuals did not reveal R257stop or K42E mutations by *Taq*I digestion. Similarly, PCR ana-

lysis of 20 unaffected Japanese was performed and no mutations were found in any of these positions. These results demonstrate that the APECED gene is responsible for the pathogenesis of APECED.

Mutations were found in the AIR-1 transcript but not in the AIR-2 and AIR-3 transcripts from all the APECED patients tested. Two Swiss and three Finnish (HP1, HP2 and MP) patients who are homozygous for the R257stop mutation completely lack functional AIR-1 protein but still have intact AIR-2 and AIR-3 proteins.

One common mutation seems responsible for the genetic defect in approximately 90% of the Finnish APECED cases and a haplotype analysis with the markers D21S141, D21S1912 and PFKL shows that the R257stop mutation is likely to be this common mutation [Björses, P. et al., Am. J. Hum. Genet. 59 (1996) 879-886].

Example 4

15 Analysis of the AIR protein expression

In this example, synthetic peptides representing amino-acid sequences of the AIR-1 protein, were used to generate a polyvalent mouse antiserum against the AIR-1 protein.

For the peptide synthesis, two peptides were chosen according to the antigenicity prediction by Pepsort program (GCC package, Wisconsin, USA). The peptides AIR-1/2 and AIR-1/6 (TLHLKEKEGCPQAFH, sequence id. no. 25 and GKNKARSSSGPKPLV, sequence id. no. 26, respectively) representing exons 2 and 6, respectively, of the APECED gene were synthesized onto a branched lysine core (Fmoc8-Lys4-Lys2-Lys-betaAla-Wang resin, Calbiochem-Novabiochem, La Jolla, Ca, USA) resulting in an octameric multible antigen peptide (MAP) [Tam, J. P. et al., Proc. Natl. Acad. Sci. USA 85 (1988) 5409-5413; Adermann, K. et al., in Solid Phase Synthesis, Biological and Biomedical Applications, pp. 429-432, Ed. R. Epton, Mayflower Worldwide Ltd., Birmingham, 1994], Syntheses were performed by Fmoc (N-9-fluorenyl)methoxycarbonyl) chemistry on a simultaneous multiple peptide synthesizer (SMPS 350, Zinsser Analytic, Frankfurt, Germany). Purity of MAPs was analyzed by reverse-phase HPLC (System Gold, Beckman Instruments Inc, Fullerton, CA, USA).

To obtain murine polyclonal antibodies, eight-week old Balb/c mice 35 were immunized with an intraperitoneal injection of 25 micrograms of each

peptide in 0,4 ml of a 1:1 mixture of Freund's Complete Adjuvant (Difco Laboratories, Detroit, Ml, USA) and physiological saline (NaCl, 0,15 M). One month later the animals were boosted with an intramuscular injection of 35 micrograms of antigens in Freund's incomplete adjuvant and saline (1:1) (0,2 ml were distributed into four sites). Three weeks later the peptides in a dose of 50 micrograms/mouse were administered intravenously and sera were obtained 7 days later.

For the production of EBV transformed B-cells, peripheral blood leukocytes were obtained from healthy control persons. The B-cells were transformed with EBV (Epstein-Barr virus) using standard protocol, and the cell lines were maintained in RPMI 1640, supplemented with 10% FCS (fetal calf serum). An aliquot of cells were stimulated for 12 hours with 10 mg/ml of phytohemagglutinin (PHA) to obtain mitogen-activated T-cells.

Tissue samples were obtained from stillborn fetuses at six months 15 gestational age. Fetal liver, spleen, thymus and lymphnodes were homogenized, the homogenates were cleared with centrifugations (20 000 rpm for 20 minutes) and the samples were used for western blot analysis.

For analysis of polyclonal sera, Elisa and western blot analysis were performed. Microtitre ELISA plates (Maxisorp, Nunc, Roskilde, Denmark) 20 were coated with the peptides (1 micrograms /well in PBS, pH 7,5) at 4^oC overnight and blocked with 2 % of BSA in PBS. The plates were then incubated with titrated mouse immune sera and normal (control) sera at room temperature for 4 h. Finally the bound peptide-specific antibodies were detected by use of anti-mouse HRP-labelled immunoglobulins (Dako A/S, Denmark) essentially as previously described [Ovod, V. A. *et al.*, AIDS 6 (1992) 25-341.

For western blotting, tissue homogenates, EBV transformed B-cells or PHA-activated T-cells were boiled for 10 minutes in 2x sample buffer (for tissue homogenates: 100 microliters of homogenate mixed with 100 microliters of sample buffer; for cells: one million cells/100 ml of buffer) and analyzed in western blotting as described in Ovod, V. A. et al., supra.

The antisera so produced reacted with the AIR-1-protein low amount in normal fetal spleen, thymus and lymphonode as well as, in EBV-transformed B-cells and in PHA-activated T-cells. In the ELISA assay towards the immunogenic peptides, all four mice gave a strong reactivity towards the peptide used for the immunization. In the western blotting analysis using either

the tissue homogenates or stimulated T-cells or established B-cells, a strong band of approx. 60 kD molecular weight was seen in fetal liver (Fig. 6), while weaker bands of the same size were seen in the other samples.

Example 5

5 Identification of the expression of APECED in thymus and other lymphoid organs

mRNA in situ hybridization and immunohistochemistry were used to identify APECED-expressing cells in various normal fetal and adult human tissues. Thymus samples were obtained in conjunction of corrective surgery 10 from cardiac patients aged 2-19 years. Other tissue samples were obtained from surgical biopsy or from autopsy material. This was approved by Hospital Ethics Committees at Tampere University Hospital and Helsinki University Central Hospital. The tissue materials were stored frozen or formaldehyde fixed and paraffin embedded until used.

For mRNA in situ hybridization, three cDNA fragments for riboprobes were amplified by RT-PCR from thymus mRNA (Clontech) with primer pairs: 5'-ATG GCG ACG GAC GCG GCG CTA CGC-'3 (seq. id. no. 27) and 5'-CCT GGA TGT ACT TCT TGG AGC CGC-3' (seq. id. no. 28), 5'-GAG CCC GAG GGG CCG TGG AGG GGA-3' (seq. id. no. 29) and 5'-GGC TGC 20 ACC TCC TGG ACT GTT GCC-3' (seq. id. no. 30), and 5'-GAT CCT GCT CAG GAG ACG TGA CCC-3' (seq. id. no. 31) and 5'-CAC CAG GCA AGG AGA GGC TCC CGG-3' (seq. id. no. 32), designed to amplify fragments spanning nucleotides 137 - 812, 738 - 1185 and 1554 - 2009 of the sequence id. no. 1, respectively. The amplified fragments were subcloned into a pCRII-25 TOPO vector (Invitrogen).

For in vitro transcription the plasmids were linearized and sense and antisense probes were synthesized with digoxigenin-UTP as described (Boehringer Mannheim Nonradioactive in situ Hybridization Application Manual). Labeled probes were purified with MicroSpinG-50 columns 30 (Pharmacia Biotech). The pretreatment and hybridization of formaldehyde fixed, paraffin embedded tissue sections were performed as described by H. Breitschopf and G. Sucharek. (Boehringer Mannheim Nonradioactive in situ Hybridization Application Manual, Detection of mRNA on paraffin embedded material of the central nervous system with DIG-labeled RNA probes, pp 136-

35 138.)

25

For the preparation of antibodies to the AIR protein, the APECED cDNA (sequences 137 - 1774 of sequence id. no. 1) containing a full-coding region was amplified from Marathon human thymus cDNA (Clontech) with primers ExF and ExR2. The primer sequences for ExF and ExR2 were 5'-5 CCA CCC CAT GGC GAC GGA CG-3' (sequence id. no. 33) and 5'-GGA ATT CGG AGG GGA AGG GGG CCG CCG GA-3' (sequence id. no. 34). The amplified cDNA was digested with Ncol and EcoRI and cloned (pHPAIRE) into pET32a vector (Novagen). The protein was expressed in E. coli and purified by His-tag as described by manufacturer (QiaExpress Type IV Kit, Cat No 10 32149, Qiagen, USA).

To obtain murine polyclonal antibodies, Balb/c mice were immunised essentially as described in Example 4 using 100 micrograms of the bacterially expressed AIR protein with booster doses of 25 and 25 micrograms.

Japanese white rabbits were immunised with a synthetic peptide representing amino acids 526-545 (DGILQWAIQSMARPAAPFPS, sequence id. no. 36) of sequence id. no. 2. The specificities of the antisera were checked with ELISA and Western blotting using standard procedures.

For immunocytochemistry, frozen sections of tissue samples were 20 fixed for 20 min in 4% paraformaldehyde. The AIR antibody (rabbit or mouse) in an appropriate dilution was incubated for 30 min at 37°C, with a biotin conjugated anti-mouse or anti-rabbit secondary antidody (Vector, CA, USA). The biotinylated antibody was revealed by incubating with Texas Red-avidin (Vector, CA, USA) for 30 min at 37°C.

With in situ hybridization, a positive signal was seen in a few cells in thymus medulla (Fig. 7A). The APECED in situ -positive cells were infrequent and scattered as single cells in the medulla, but occasionally one or two APECED-expressing cells were seen adjacent to or buried into the Hassal's corpuscles that represent conglomerates of medullary epithelial cells. In the 30 positive cells, APECED mRNA was predominantly localized in the cell nucleus. In human adult lymph node tissues, infrequent cells expressed APECED mRNA in the medulla and occasionally in the paracortical region, too (Fig. 7B) No hybridization signal was seen in the germinal centers.

Immunohistochemistry with mouse and rabbit polyclonal antisera to 35 the AIR protein showed strong reactivity with selected cells in thymus medulla, lymph nodes and fetal liver (Fig. 7C and 7D) The comparison of the reaction

pattern obtained by immunohistochemistry to that obtained by in situ hybridization clearly established that specific, rare cells in thymus medulia and lymph node medulla and paracortex express APECED mRNA and the AIR protein. By either method, neither mRNA nor protein was detected in other 5 adult tissues studied, including the target organs for tissue destruction in APECED (adrenal glands, parathyroid glands, gonads). In human fetal tissues, APECED positive cells were seen, although extremely infrequently, in the stroma of placental chorionic villi and in the sinusoidal area of the liver. In the fetal liver, the APECED positive cells were often localized pairwise like mirror 10 images, suggesting that the cells were undergoing mitosis. Rare APECED expressing cells were also found in fetal thymus but the expression was not observed in other fetal tissues.

At the subcellular level, the AIR protein localized in small nuclear dots in the adult thymus, giving a characteristic speckled pattern (Fig. 7C; and 15 Fig. 8A and 8B), but localized in the cytoplasm of cells in lymph nodes. In the rare positive cells in fetal liver, many of which were mitotic, the AIR protein was localized in the cytoplasm.

Example 6

25

Characterization of the phenotype of the APECED positive cells in 20 thymus

Double staining with two antibodies was used to further characterize the cell type expressing APECED gene. In view of the fact that dendritic cells (DC) and thymus epithelium are both involved in the regulation of immune maturation, expression of markers for these cells were studied.

For double immunofluorencence detection the AIR staining was performed as described in example 5 with rabbit anti-AIR serum. The slides were then incubated with a second primary antibody [AE1 (Neomarkers, CA, USA), AE3 (Neomarkers, CA, USA), CD11c (Immunotech, France), or CD83 (Immunotech, France)] in an appropriate dilution for 30 min at 37°C, and the 30 reaction was revealed by incubating with a FITC conjugated secondary antimouse antibody (Vector, CA, USA) for 30 min at 37°C.

Antibodies reacting with low molecular weight basic (AE1) or high molecular weight acidic (AE3) cytokeratins stained the thymus in a reticular fashion, and the APECED positive cells were seen either buried into this net 35 or in close apposition with the keratin-positive cells. Confocal microscopy clearly demonstrated that some of the APECED positive cells were cytokeratin positive while some remained negative (Figure 8A). A colocalization was stronger with AE1 than with AE3. The distribution of epithelial (AE1 positive) and non-epithelial APECED expressing cells varied but in most thymus preparates more than half were epithelial.

Less than half of the APECED expressing cells in thymus stained with markers CD11c and CD83 that react with cells of the monocyte-macrophage-dendritic cell lineage. In most cases, the staining reaction was weak but a few cells showed an intensive staining with the given marker (Fig. 8B). CD83 costained 5 to 40 % of the APECED positive cells. Antibody CD11c, reported to be specific for mature dendritic cells, reacted with up to 5 - 10 % of the APECED positive cells. All APECED positive cells were strongly positive for HLA-DR staining, however (data not sown).

These results suggest that in thymus the APECED gene is in fact expressed in two distinct cell populations, one epithelial and the other non-epithelial. The latter cell type is likely the one also expressing the APECED gene in extrathymic lymphoid tissues.

Example 7

APECED expression in stimulated dendritic cells in vitro

To show an APECED expression in dendritic cells derived from peripheral blood monocytes that are DC precursors, these cells were cultured at the presence of cytokines using conditions that are known to lead to the expansion and maturation of dendritic cells.

Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque centrifugation, and adherent cells were separated and cultured in the presence of human recombinant GM-CSF (1000 units/ml) and rhIL-4 (1000 units/ml, both from R&D Systems), as described [Schuler, G. and Romani, N., Adv. Exp. Med. Biol. 417 (1997) 7 - 13]. Cells were further cultured for three days with 1/4 V/V of macrophage conditioned media. Cells were harvested at two days intervals and samples were prepared for RT-PCR. For RT-PCR total RNA was purified from DCs by using a commercial kit from Clontech (USA) (Nucleospin RNA Kit) according to manufacturer's instructions. An aliquot of RNA was transferred into cDNA with a commercial kit from Pharmacia (Sweden) (First-strand Synthesis Kit) and PCR for this DNA sample was performed. For PCR the fragment was amplified with primers 5'- GAT CCT

GCT CAG GAG ACG TGA CCC-3' (seq. id. no. 31; 1554 -1577 of seq. id. no. 1) and 5'-GGA CTG AGG AAG GAG GTG TCC TTC -3' (seq. id. no. 35; 1818-1841 of seq. id. no. 1) with the following conditions: 35 cycles of 95°C for 1 min., 62°C for 30 sec and 72°C for 1 min. The 1x reaction mix contained 50mM KCl, 10mM Tris-HCl, pH8.3, 1.5mM MgCl₂, 0.001% (w/v) gelatin, 0.2mM each of dNTPs, 0.25 U of Dynazyme (Finnzymes, Finland). A fragment of 287bp was detected by 1.5% agarose electrophoresis.

Cytospin preparations were further made for immunohistochemistry.

During this 7 to 10 days culture period approximately half of the

cells developed the characteristic veiled morphology of DC and their phenotypic cell markers (CD11cand CD83) corresponded to mature DCs (Figure 9). The APECED expression was studied by RT-PCR and immunocytochemistry at two to three days intervals. In the starting material, i.e. the adherent cell pool from peripheral blood, no APECED expression was found. After seven days of culture in the presence of GM-CSF and IL-4, RT-PCR showed APECED mRNA expression and immunofluorescence showed a few AIR specific nuclear dots. After an additional 3-day-culture with conditioned medium from macrophage cultures a strong speckled pattern of nuclear AIR expression was seen (Figure 9A). The RT-PCR analysis of the mature (10 days) culture confirmed the AIR protein expression.

SEQUENCE LISTING

- (i) APPLICANT:
 - (A) NAME: Kai Krohn et al.
 - (B) STREET: Iltarusko, Salmentaantie 751
 - (C) CITY: 36450 Salmentaka
 - (E) COUNTRY: Finland
 - (F) POSTAL CODE (ZIP): none
- (ii) TITLE OF INVENTION: Novel Gene
- (iii) NUMBER OF SEQUENCES: 26
- (iv) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
- (2) INFORMATION FOR SEQ ID NO: 1:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2036 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 137..1774
 - (D) OTHER INFORMATION:/product= "AIR-1"
 - (ix) FEATURE:
 - (A) NAME/KEY: mat_peptide
 - (B) LOCATION: 137...1771
 - (D) OTHER INFORMATION:/product= "AIR-1"
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
- AGACCGGGGA GACGGGCGGG CGCACAGCCG GCGCGGAGGC CCCACAGCCC CGCCGGGACC 60
- CGAGGCCAAG CGAGGGGCTG CCAGTGTCCC GGGACCCACC GCGTCCGCCC CAGCCCCGGG 120
- TCCCCGCGCC CACCCC ATG GCG ACG GAC GCG GCG CTA CGC CGG CTT CTG 169

Met Ala Thr Asp Ala Ala Leu Arg Arg Leu Leu

1 5 10

AGG CTG CAC CGC ACG GAG ATC GCG GTG GCC GTG GAC AGC GCC TTC CCA 217

	CIG															
Arg	Leu	His	Arg 15	Thr	Glu	Ile .	Ala '	Val 20	Ala	Val	Asp	Ser	Ala 25	Phe	Pro	
CTG	CTG	CAC	GCG	CTG	GCT	GAC	CAC	GAC	GTG	GTC	CCC	GAG	GAC	AAG	TTT	265
												Glu				
		30					35					40				
												ccc				313
Gln	Glu 45	Thr	Leu	His	Leu	Lys 50	Glu	Lys	Glu	Gly	Cys 55	Pro	Gln	Ala	Phe	
CAC	GCC	CTC	CTG	TCC	TGG	CTG	CTG	ACC	CAG	GAC	TCC	ACA	GCC	ATC	CTG	361
												Thr				
60					65					70					7 5	
												GAG				409
Asp	Phe	Trp	Arg	Val 80	Leu	Phe	Lys	Asp	Tyr 85	Asn	Leu	Glu	Arg	Tyr 90	Gly	
000	cmc	מזר	CCC	አምሮ	כייוכ	GAC	AGC.	ጥጥር	ccc	ΔΔΔ	GAT	GTG	GAC	CTC	AGC	457
												Val				
	200		95			•		100					105			
												AAG				505
Gln	Pro	Arg	Lys	Gly	Arg	Lys	Pro	Pro	Ala	Val	Pro	Lys	Ala	Leu	Val	
		110					115					120				
ccc	CCA	רכר	AGA	CTC	CCC	ACC	AAG	AGG	AAG	GCC	TCA	GAA	GAG	GCT	CGA	553
															Arg	
	125		Ĩ			130					135					
GCT	GCC	GCG	CCA	GCA	GCC	CTG	ACT	CCA	AGG	GGC	ACC	GCC	AGC	CCA	GGC	601
Ala	Ala	Ala	Pro	Ala	Ala	Leu	Thr	Pro	Arg	Gly	Thr	Ala	Ser	Pro	Gly	
140					145					150					155	
															GAG	649
Ser	Gln	Lev	Lys			Pro	Pro	Lys		Pro	Glu	Ser	Ser		Glu	
				160					165					170		
CAG	CAG	CGC	CTI	CCA	CTC	GGG	AAC	GGG	ATT	CAG	ACC	ATG	TCA	GCI	TCA	697
Gln	Gln	Arç	175		Leu	Gly	Asn	180		GIT	Tnr	met	185		ser	
CTC	י ראפ	: AGI	A GCT	GTG	GCC	ATG	TCC	TCC	GGG	GAC	GTO	cce	GGZ	GCC	C CGA	745
															a Arg	
		190					195					200				
															C GGC	793
Gl	y Ala	a Va	l Gl	ı Gly	/ Ile	Let	116	e Gl	n Glr	Va.			ı Se:	c Gl	y Gly	
	205					210					21					
															C AAG	843
		s Ly	s Cy	s Ile			Gl	y Gl	y Gli			r Th	r Pr	o Se	r Lys	
22	0				225	ס				23	U				235	

			TCC													889
?he	Glu	Asp	Ser	Gly 240	Ser	Gly	Lys		Lys 245	Ala	Arg	Ser		Ser 250	Gly	
ace	AAG	CCT	CTG	GTT	CGA	GCC	AAG	GGA	GCC	CAG	GGC	GCT	GCC	ccc	GGT	937
			Leu 255									Ala				
GGA	GGT	GAG	GCT	AGG	CTG	GGC	CAG	CAG	GGC	AGC	GTT	ccc	GCC	CCT	CTG	985
			Ala													
GCC	CTC	ccc	AGT	GAC	ccc	CAG	CTC	CAC	CAG	AAG	AAT	GAG	GAC	GAG	TGT	1033
Ala	Leu 285	Pro	Ser	Asp	Pro	Gln 290	Leu	His	Gln	Lys	Asn 295	Glu	Asp	Glu	Cys	
ccc	CTC.	un Carr	CGG	GAC	GGC	GGG	GAG	CTC	ATC	TGC	TGT	GAC	GGC	TGC	CCT	1081
			Arg													
300		-	_		305					310					315	
CGG	GCC	TTC	CAC	CTG	GCC	TGC	CTG	TCC	CCT	CCG	CTC	CGG	GAG	ATC	ccc	1129
			His											Ile		
				320					325					330		
			TGG													1177
Ser	Gly	Thr	Trp 335	Arg	Cys	Ser	Ser	Cys 340	Leu	Gln	Ala	Thr	Val 345	Gln	Glu	
GTG	CAG	ccc	CGG	GCA	GAG	GAG	ccc	CGG	CCC	CAG	GAG	CCA	ccc	GTG	GAG	1225
Val	Gln	Pro 350	Arg	Ala	Glu	Glu	Pro 355	Arg	Pro	Gln	Glu	360	Pro	Val	Glu	
			ccc													1273
Thr			Pro	Pro	Gly			Ser	Ala	Gly			Val	Arg	Gly	
	365					370					375)				
			GAA													1321
		Gl ₃	/ Glu	Pro			Gly	Met	Asp			Leu	Val	Tyr	Lys 395	
380	}				385	•				390	,				393	
															TCC	1369
His	Leu	ı Pro	Ala			Ser	Ala	Ala	405		ı Pro	o Gly	Leu	Asp 410	Ser	
				400	,				403	,				41/	,	
															G AAC	1417
Se	r Ala	a Le	u His 419		Let	ı Let	ı Cys	420		y Pr	o Gl	u Gly	7 Glr 425		n Asn	
															C GTG	1465
Le	u Al			y Ala	a Ar	g Cy:			l Cy	s Gl	y As			As:	p Val	
		43	υ				43	.				440	•			

CTG	CGG	TGT	ACT	CAC	TGC	GCC	GCT	GCC	TTC	CAC	TGG	CGC	TGC	CAC	TTC	1513
Leu	Arg	Cys	Thr	His	Cys	Ala	Ala	Ala	Phe	His	Trp	Arg	Cys	His	Phe	
	445					450					455					
CCD	ccc	ccc	∆CC	TCC	CGG	CCC	GGG	ACG	GGC	CTG	CGC	TGC	AGA	TCC	TGC	1561
				Ser												
460	AIG	01,			465		•		-	470	•	-	_		475	
				ACC												1609
Ser	Gly	Asp	Val	Thr	Pro	Ala	Pro	Val		Gly	Val	Leu	Ala		Ser	
				480					485					490		
CCC	GCC	CGC	CTG	GCC	CCT	GGG	CCT	GCC	AAG	GAT	GAC	ACT	GCC	AGT	CAC	1657
				Ala												
			495					500					505			
				CAC												1705
Glu	Pro		Leu	His	Arg	Asp		Leu	Glu	Ser	Leu		Ser	GIu	His	
		510					515					520				
ארר	ጥጥር	GAT	GGC	ATC	CTG	CAG	TGG	GCC	ATC	CAG	AGC	ATG	GCC	CGT	CCG	1753
															Pro	
	525		-			530					535					
				ccc			CCC	CAGA	TGG	CCGG	GACA	TG C	AGCT	CTGA	T	1804
		Pro	Phe	Pro												
540					545	1										
GAG	AGAG	TGC	TGAG	AAGG	AC A	CCTC	CTTC	C TC	AGTO	CTGG	AAC	CCGG	CCG	GCTG	GGATCA	1864
AGA	AGGG	GAC	AGCG	CCAC	CT	TTGT	CAG	G CI	CGGC	TGTA	AAC	AGCI	CTG	TGTT	TCTGGG	1924
		~~~	3 m C 7	meme	יכר ח	oca,	יייי איני	א אר	ጉርርጥር	ברררר	י אריי	ייייטייי	יייאכי	TCTC	GAAGTC	1984
GAC	ACCA	IGCC	ATC	TGTG	ا کان	GGAF	rw 1 1 t	ın nı					inc	1010	0.11.010	250.
CCC	GGGA	GCC	TCTC	CTTC	SCC T	GGT	SACC:	ra Ci	'AAA'	LATA	TAA 1	AAT	ragc	TG		2036
										_						
(2	) II	NFOI	RMAI	NOI	I FO	R S	EQ :	ID 1	10:	2:						
		1	: \ C	SEQU	IFN(	EC	HAR	ነ ምን ፈ	RTS	TTC	!S:					
		١.		A) I												
				3) 1												
				2) ]												
							_									
	(	ii)	MO]	LEC	JLE	TYP	E:	bro.	teir	_ un	, T.	. NTA	. ^			
	(	xi)	SE	2UE1	NCE	DES	CRI	PTI	JN:	SEÇ	i Th	, NO	: 2	•		

Met Ala Thr Asp Ala Ala Leu Arg Arg Leu Leu Arg Leu His Arg Thr
1 5 10 15

Glu Ile Ala Val Ala Val Asp Ser Ala Phe Pro Leu Leu His Ala Leu  $20 \hspace{1cm} 25 \hspace{1cm} 30$ 

Ala Asp His Asp Val Val Pro Glu Asp Lys Phe Gln Glu Thr Leu His 35 40 45

Leu	Lys 50	Glu	Lys	Glu	Gly	Cys 55	Pro	Gln	Ala	Phe	His 60	Ala	Leu	Leu	Ser
Prp 65	Leu	Leu	Thr	Gln	Asp 70	Ser	Thr	Ala	Ile	Leu 75	Asp	Phe	Trp	Arg	Val 80
Leu	Phe	Lys	Asp	Tyr 85	Asn	Leu	Glu	Arg	Туг 90	Gly	Arg	Leu	Gln	Pro 95	Ile
Leu	Asp	Ser	Phe 100	Pro	Lys	Asp	Val	Asp 105	Leu	Ser	Gln	Pro	Arg 110	Lys	Gly
Arg	Lys	Pro 115	Pro	Ala	Val	Pro	Lys 120	Ala	Leu	Val	Pro	Pro 125	Pro	Arg	Leu
Pro	Thr 130	Lys	Arg	Lys	Ala	Ser 135	Glu	Glu	Ala	Arg	Ala 140	Ala	Ala	Pro	Ala
Ala 145	Leu	Thr	Pro	Arg	Gly 150	Thr	Ala	Ser	Pro	Gly 155	Ser	Gln	Leu	Lys	Ala 160
Lys	Pro	Pro	Lys	Lys 165	Pro	Glu	Ser	Ser	Ala 170	Glu	Gln	Gln	Arg	Leu 175	Pro
Leu	Gly	Asn	Gly 180	Ile	Gln	Thr	Met	Ser 185	Ala	Ser	Val	Gln	Arg 190	Ala	Val
Ala	Met	Ser 195	Ser	Gly	Asp	Val	Pro 200	Gly	Ala	Arg	Gly	Ala 205	Val	Glu	Gly
Ile	Leu 210	Ile	Gln	Gln	Val	Phe 215	Glu	Ser	Gly	Gly	Ser 220		Lys	Cys	Ile
Gln 225	Val	Gly	Gly	Glu	Phe 230	Tyr	Thr	Pro	Ser	Lys 235		Glu	Asp	Ser	Gly 240
				245					250					Leu 255	
Arg	Ala	Lys	Gly 260		Gln	Gly	Ala	Ala 265		Gly	Gly	Gly	Glu 270	Ala	Arg
Leu	Gly	Gln 275		Gly	Ser	Val	Pro 280		Pro	Lev	a Ala	285		Ser	Asp
Pro	Gln 290		His	Gln	Lys	295		Asp	o Glu	ı Cys	300		L Cys	arg	Asp
305					310	)				31	5			e His	320
Ala	Cys	Let	ı Ser	225		Leu	ı Arç	, Glı	ı Il∈ 330		Se:	r Gl	y Thi	r Trp 335	

Cys Ser Ser Cys Leu Gln Ala Thr Val Gln Glu Val Gln Pro Arg Ala 340 345 350

Glu Glu Pro Arg Pro Gln Glu Pro Pro Val Glu Thr Pro Leu Pro Pro 355 360 365

Gly Leu Arg Ser Ala Gly Glu Glu Val Arg Gly Pro Pro Gly Glu Pro 370 380

Leu Ala Gly Met Asp Thr Thr Leu Val Tyr Lys His Leu Pro Ala Pro 385 390 395 400

Pro Ser Ala Ala Pro Leu Pro Gly Leu Asp Ser Ser Ala Leu His Pro 405 410 415

Leu Leu Cys Val Gly Pro Glu Gly Gln Gln Asn Leu Ala Pro Gly Ala 420 425 430

Arg Cys Gly Val Cys Gly Asp Gly Thr Asp Val Leu Arg Cys Thr His
435 440 445

Cys Ala Ala Ala Phe His Trp Arg Cys His Phe Pro Ala Gly Thr Ser 450 460

Arg Pro Gly Thr Gly Leu Arg Cys Arg Ser Cys Ser Gly Asp Val Thr 465 470 475 480

Pro Ala Pro Val Glu Gly Val Leu Ala Pro Ser Pro Ala Arg Leu Ala 485 490 495

Pro Gly Pro Ala Lys Asp Asp Thr Ala Ser His Glu Pro Ala Leu His 500 505 510

Arg Asp Asp Leu Glu Ser Leu Leu Ser Glu His Thr Phe Asp Gly Ile 515 520 525

Leu Gln Trp Ala Ile Gln Ser Met Ala Arg Pro Ala Ala Pro Phe Pro 530 535 540

Ser * 545

- (2) INFORMATION FOR SEQ ID NO: 3:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 1545 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear

(ix) FEATURE:

	(IX		(A) (B) (D)	NAN LOC	ME/K CATI	ON:	237	12		'pro	oduc	t= '	"AIF	R-2 <b>'</b>	•	
	(i×	() F	(A) (B)	NAI LOC	ME/K CATI	ON:	237	1	280		oduc	t=	"AII	R-2'	,	
	(xi	L) S	EQUI	ENC	E DE	ESCR	IPT	ION	: Si	EQ I	ID N	0:	3:			
AGAG	AAAG'	TG A	GGTCI	TCT	C AGO	GCTC:	AATI	GAG	CATGO	SCG :	TTTG	STCCA	AG GC	TGT	ACCCG	60
CTGC'	TCTC.	AG C	rggg	cccg	T GG	GTGG	GCCG	GGC	SCCC	CTG (	CTATA	AGCC	AG GA	AGGT	CAAGG	120
ATCC.	ACTG	GG A	ATGC	CATG	C TC	ATCT'	TTCG	TCC	CCAG	CAT :	GGTT'	rctt2	AA TO	GGGG	TAGAA	180
GCAG	GTCG	GG A	GAGA	CCTC	C CT	GGGC	CTGG	CCC	CACT	GCC	CTGT	GAGG	AA G	GGTT	С	236
		TTG Leu														284
		CGG Arg														332
		CCA Pro 35														380
		AGC Ser														428
AGA Arg 65	TGC Cys	TGC Cys	TGG Trp	GGG Gly	AGC Ser 70	TGT Cys	TTT Phe	GGG Gly	AAG Lys	GAG Glu 75	GTG Val	GCT Ala	CTC Leu	AGG Arg	AGG Arg 80	476
GTG Val	CTG Leu	CAC	CCC Pro	AGC Ser 85	Pro	GTC Val	TGC Cys	ATG Met	GGC Gly 90	GTC Val	TCT Ser	TGC Cys	CTG Leu	TGC Cys 95	CAG Gln	524
AAG Lys	AAT Asn	GAG	GAC Asp 100	Glu	TGT Cys	GCC	GTG Val	TGT Cys 105	Arg	GAC Asp	GGC Gly	GGG Gly	GAG Glu 110	CTC Leu	ATC Ile	572
TGC Cys	TGT Cys	GAC Asp 115	Gly	TGC Cys	CCT Pro	CGG	GCC Ala	Phe	CAC His	CTG Leu	GCC Ala	TGC Cys 125	Leu	TCC Ser	CCT Pro	620

700	ama	ccc	CAC	<b>ልጥ</b> ሮ	CCC	TOA	GGG	ACC	TGG	AGG	TGC	TCC	AGC	TGO	: c	TG	668
Pro	Leu	Ara	Glu	Ile	Pro	Ser	Gly	Thr	Trp	Arg	Cys	Ser	Ser	Cys	s I	eu	
	130	9				135					140						
CAG	GCA	ACA	GTC	CAG	GAG	GTG	CAG	CCC	CGG	GCA	GAG	GAG	CCC	CGG	G (	CCC Pro	716
	Ala	Thr	Val	Gln		Val	Gln	Pro	Arg	155	GIU	GIU	PIO	AT.		160	
145					150					100							
CAG	GAG	CCA	CCC	GTG	GAG	ACC	CCG	CTC	ССС	CCG	GGG	CTT	AGG	TC	G (	<b>GC</b> G	764
Gln	Glu	Pro	Pro	Val	Glu	Thr	Pro	Leu	Pro	Pro	Gly	Leu	Arg	Se	r i	Ala	
				165					170					17	5		
			cm.	7.07	CCT	CCN	CCT	GGG	CDD	רכר	ሮሞል	GCC	GGC	: AT	G (	GAC	812
GGA	GAG	GAG	GTA	AGA	GGT	Pro	Pro	Gly	Glu	Pro	Leu	Ala	Gly	, Me	t	Asp	0.1.2
GIY	GLU	GIU	180	nry	013			185					190			-	
ACG	ACT	CTT	GTC	TAC	AAG	CAC	CTG	CCG	GCT	CCG	CCT	TCI	GC	4 GC	С	CCG	860
Thr	Thr	Leu	Val	Tyr	Lys	His		Pro	Ala	Pro	Pro			a Al	a	Pro	
		195					200					205					
<b>c</b> mc	CCT	ccc	ርጥር	: GAC	TCC	TCG	GCC	CTG	CAC	ccc	CTA	CTO	TG'	r GT	'G	GGT	. 908
								Leu									
	210			-		215					220						
																<b></b>	0.5.6
								CCT									956
		Gly	Glr	Gln	230		Ala	Pro	GIY	235		g Cy:	S G1	y va	11	240	
225					230	,				200							
GGA	GAT	GGT	r ACC	GAC	GTG	CTO	CGG	G TGI	ACI	CAC	TG	C GC	C GC	T G	CC	TTC	1004
Gly	Asp	G15	Thi	Asp	Val	Let	Arc	g Cys	Thr	His	з Су	s Al	a Al	a Ai	lα	Phe	
				245	5				250	)				2	55		
			- mc/	- ~~	- mm		\	c GGC	י אכנ	י ייי	r ce	s cc	c gg	G A	CG	GGC	1052
								a Gly									
nia		, mr.	26					265					27				
								A GA									1100
Let	ı Arç			g Se:	r Cy	s Se		y Ası	o Va.	l Th	r Pr	0 A.I 28		:0 V	аı	GIN	
		27	5				28	U				20	J				
GGC	3 GT(	з ст	G GC	c cc	C AG	c cc	C GC	c cg	C CT	G GC	c cc	T GG	G C	T G	СC	AAG	1148
Gl	y Vai	l Le	u Al	a Pr	o Se	r Pr	o Al	a Ar	g Le	u Al	a Pr	o G1	у Р	o A	1 a	Lys	
	29	0				29	5				30	0					
					_ ~-	~ ~~			m cm	C C1	.C 7.C	:c c7	ייי כו	מר ר	ייים:	GAG	1196
GA'	T GA	C AC	T GC	.C AG	T CA	C GA	ii Pr	C GC	a Le	u Hi	s Ar	a As	n A	sp I	.eu	Glu	1130
30		ртп	I AL	a 5e	31	_			u <b>-</b> -	31			•	•		320	
TC	C CT	T CI	G AC	C GA	G CA	C AC	C TI	C GA	T GG	C A	C C	rg C	AG T	GG (	SCC	ATC	1244
Se	r Le	u Le	eu Se			s Th	r Pr	ne As			Le Le	eu G	ln T			lle	
				32	25				33	30				-	335	•	
~-	C 30	יר אי	מים כי	יר רי	בידי רי	ig er	ig go	cc cc	ריד כ	rc co	CC T	CC T	GA C	ccci	AGZ	ATGG	1293
								la Pi					*				
				10	-			34									

CCGGGACATG CAGCTCTGAT GAGAGAGTGC TGAGAAGGAC ACCTCCTTCC TCAGTCCTGG	1353
AAGCCGGCCG GCTGGGATCA AGAAGGGGAC AGCGCCACCT CTTGTCAGTG CTCGGCTGTA	1413
AACAGCTCTG TGTTTCTGGG GACACCAGCC ATCATGTGCC TGGAAATTAA ACCCTGCCCC	1473
ACTTCTCTAC TCTGGAAGTC CCCGGGAGCC TCTCCTTGCC TGGTGACCTA CTAAAAATAT	1533 1545
AAAAATTAGC TG	1545
(2) INFORMATION FOR SEQ ID NO: 4:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS: <ul> <li>(A) LENGTH: 348 amino acids</li> <li>(B) TYPE: amino acid</li> <li>(D) TOPOLOGY: linear</li> </ul> </li> <li>(ii) MOLECULE TYPE: protein</li> <li>(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:</li> </ul>	
Met Trp Leu Val Tyr Ser Ser Gly Ala Pro Gly Thr Gln Gln Pro Ala 1 5 10 15	
Arg Asn Arg Val Phe Phe Pro Ile Gly Met Ala Pro Gly Gly Val Cys 20 25 30	
Trp Arg Pro Asp Gly Trp Gly Thr Gly Gly Gln Gly Arg Ile Ser Gly 35 40 45	
Pro Gly Ser Met Gly Ala Gly Gln Arg Leu Gly Ser Ser Gly Thr Gln 50 55 60	
Arg Cys Cys Trp Gly Ser Cys Phe Gly Lys Glu Val Ala Leu Arg Arg 65 70 75 80	
Val Leu His Pro Ser Pro Val Cys Met Gly Val Ser Cys Leu Cys Gln 85 90 95	
Lys Asn Glu Asp Glu Cys Ala Val Cys Arg Asp Gly Glu Leu Ile 100 105 110	
Cys Cys Asp Gly Cys Pro Arg Ala Phe His Leu Ala Cys Leu Ser Pro 115 120 125	
Pro Leu Arg Glu Ile Pro Ser Gly Thr Trp Arg Cys Ser Ser Cys Leu 130 135 140	
Gln Ala Thr Val Gln Glu Val Gln Pro Arg Ala Glu Glu Pro Arg Pro 145 150 155 160	

Gln	Glu	Pro	Pro	Val	Glu	Thr	Pro	Leu	Pro	Pro	Gly	Leu	Arg	Ser	Ala
				165					170					175	

- Gly Glu Glu Val Arg Gly Pro Pro Gly Glu Pro Leu Ala Gly Met Asp 180 185 190
- Thr Thr Leu Val Tyr Lys His Leu Pro Ala Pro Pro Ser Ala Ala Pro 195 200 205
- Leu Pro Gly Leu Asp Ser Ser Ala Leu His Pro Leu Leu Cys Val Gly 210 215 220
- Pro Glu Gly Gln Gln Asn Leu Ala Pro Gly Ala Arg Cys Gly Val Cys 225 230 235 240
- Gly Asp Gly Thr Asp Val Leu Arg Cys Thr His Cys Ala Ala Ala Phe 245 250 255
- His Trp Arg Cys His Phe Pro Ala Gly Thr Ser Arg Pro Gly Thr Gly 260 265 270
- Leu Arg Cys Arg Ser Cys Ser Gly Asp Val Thr Pro Ala Pro Val Glu 275 280 285
- Gly Val Leu Ala Pro Ser Pro Ala Arg Leu Ala Pro Gly Pro Ala Lys 290 295 300
- Asp Asp Thr Ala Ser His Glu Pro Ala Leu His Arg Asp Asp Leu Glu 305 310 315 320
- Ser Leu Leu Ser Glu His Thr Phe Asp Gly Ile Leu Gln Trp Ala Ile 325 330 335
- Gln Ser Met Ala Arg Pro Ala Ala Pro Phe Pro Ser * 340 345
- (2) INFORMATION FOR SEQ ID NO: 5:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 1463 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ix) FEATURE:
    - (A) NAME/KEY: CDS
    - (B) LOCATION: 237..1001
    - (D) OTHER INFORMATION:/product= "AIR-3"
  - (ix) FEATURE:
    - (A) NAME/KEY: mat_peptide
    - (B) LOCATION: 237..998
    - (D) OTHER INFORMATION:/product= "AIR-3"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5
(XI) DD20m10

	(22.1	., .	, <u>D</u> Q O							_						
AGAG	AAAG'	rg A	GGTC:	rtctc	AGG	CTCI	'TAA	GAG	CATGO	GCG '	TTTG	STCCA	.G GC	TGT	CCCG	60
CTGC	TCTC	AG C	TGGG	CCCGI	GGG	STGGG	CCG	GGC	GCCC	CTG	CTAT	AGCCA	G GA	GGT	CAAGG	120
ATCC	ACTG	GG A	ATGC	CATGO	TCF	ATCTI	TCG	TCC	CCAG	CAT	GGTT'	TCTTA	A TG	GGG:	ragaa	180
GCAG	GTCG	GG A	GAGA	CCTC	CTC	GGC	CTGG	CCC	CACT	GCC	CTGT	GAGG	A GO	GTT	2	236
ATG Met	TGG Trp	T <b>T</b> G Leu	GTG '	TAC A Tyr :	AGT :	rcc ( Ser (	ege (	GCC ·	CCT (Pro	GGA Gly	ACG Thr	CAG (	CAG (	CT (Pro 2	GCA Ala	284
												GGG (				332
												AGA Arg				380
CCT Pro	GGC Gly 50	AGC Ser	ATG Met	GGA Gly	GCA Ala	GGG Gly 55	CAG Gln	AGA Arg	CTG Leu	GGG Gly	AGT Ser 60	TCA Ser	GGT .	ACC Thr	CAG Gln	428
												GCT Ala				476
GTG Val	CTG Leu	CAC His	CCC Pro	AGC Ser 85	CCA Pro	GTC Val	TGC Cys	ATG Met	GGC Gly 90	GTC Val	TCT Ser	TGC Cys	CTG Leu	TGC Cys 95	CAG Gln	524
												GGG				572
TGC Cys	TGT Cys	GAC Asp	Gly	TGC Cys	CCT Pro	Arg	GCC Ala 120	Phe	CAC His	CTG	GCC Ala	TGC Cys 125	CTG Leu	TCC Ser	CCT Pro	620
CCG Pro	CTC Lev	Arç	GAG Glu	ATC	CCC Pro	AGT Ser 135	GGG Gly	ACC	TGG	AGG Arg	TGC Cys	TCC Ser	AGC Ser	TGC Cys	CTG Leu	668
CAC Glr 145	a Ala	A ACA	A GTC r Val	CAG Gln	GAG Glu 150	Val	CAG Glr	CCC Pro	CGG Arg	GCA J Ala 15	a Glu	GAG 1 Glu	CCC	CGG	Pro 160	716
CA(	G GAG	s cc	A CCC	GTG Val	Glu	ACC Thr	CCC	G CTO	C CCC	o Pr	G GGG	G CTT y Leu	AGG Arg	TCC Ser	Ala	764

CC3	C7 C	CAC	ccc	cec	ጥርር	CAG	GGC	TGG	ACT	CCT	CGG	CCC	TGC	ACC	ccc	812
														Thr		
<b>-</b> ,			180	-	-			185					190			
									3.03	3.00	mcc	ርሞር	CWC.	CTC.	CCC	860
														GTG Val		000
Tyr	Cys	195	ттр	Vai	Ten	AIG	200	261	nig			205	200		5	
		100														
														CTC		908
Val	Ala	Gly	Cys	Ala	Glu		Val	Arg	Thr	Cys		Gly	Val	Leu	Thr	
	210					215					220					
ccc	ccc	CTG	ርርሞ	TCC	ACT	GGC	GCT	GCC	ACT	TCC	CAG	CCG	GCA	CCT	CCC	956
														Pro		
225					230					235					240	
																1001
														TGA *		1001
Gly	Pro	GIY	Arg	A1a 245	Cys	Ala	Ald	Asp	Pro 250	AIA	GIII	GIU	1	255		
				245												
ccc	CAGC	ccc	TGTG	GAGG	GG G	TGCT	GGCC	c cc	AGCC	CCGC	CCG	CCTG	GCC	CCTG	GGCCTG	1061
CCA	AGGA	TGA	CACT	GCCA	GT C	ACGA	GCCC	G CI	CTGC	ACAG	GGA	TGAC	CTG	GAGT	CCCTTC	1121
TGA	.GCGA	GCA	CACC	TTCG	AT G	GCAT	CCTG	C AG	TGGG	CCAT	CCA	.GAGC	ATG	GCCC	:GTCCGG	1181
ree	כככר	יריים.	cccc	TCCT	'GA C	CCCA	.GATG	G CC	GGGA	CATG	CAG	CTCI	GAT	GAGA	GAGTGC	1241
TGA	.GAAG	GAC	ACCI	CCTI	CC I	CAGI	CCTG	G A	AGCCG	GCCG	GCI	'GGG#	TCA	AGAA	AGGGGAC	1301
AGC	:GCCF	CCT	CTT	TCAC	TG C	TCGC	CTGT	'A A	CAGO	TCTO	; TGI	TTCI	'GGG	GACA	ACCAGCC	1361
ATO	ATG	rgcc	TGG	LTAAL	AA A	CCCI	GCCC	C A	CTTCI	CTAC	TCI	GGAZ	AGTC	cccc	GGAGCC	1421
																1463
TCT	CCT	rgcc	TGG	rgaco	CTA	TAA	\AAT?	AT A	'AAAA	TAGO	TG					1463
(2	) I	NFO	RMA?	rion	FO	R S	EQ :	ID Ì	10:	6:						
		,	i )	SEOU	IENC	E C	HAR	ACTI	ERIS	TIC	s:					
		١.	+, . (2	A) I	ENG	TH:	25	4 aı	nino	ac	ids					
							min									
			(1	D) 7	OPC	LOG	Υ:	lin	ear							
	,	::1	M∩'	፣ ፍርግ	II.F	ጥላኮ	F. •	nro	teir	٦						
	( 1	<u>11</u>	SF.	OUE	NCE	DES	CRI	PTI	ON:	SEÇ	) ID	NO	: 6	:		
Me	t Tr	p Le	u Va	1 Ty	r Se	r Se	r Gl	y Al	a Pr	o Gl	y Th	r Gl	n Gl	n Pr	o Ala	

Arg Asn Arg Val Phe Phe Pro Ile Gly Met Ala Pro Gly Gly Val Cys
20 25 30

10

1 5

Trp Arg Pro Asp Gly Trp Gly Thr Gly Gly Gln Gly Arg Ile Ser Gly 35  $\phantom{\bigg|}40\phantom{\bigg|}45\phantom{\bigg|}$ 

Pro Gly S	Ser Met	Gly Ala	Gly	Gln Arg	, Leu	Gly	Ser	Ser	Gly	Thr	Glr
50			55				60				

- Arg Cys Cys Trp Gly Ser Cys Phe Gly Lys Glu Val Ala Leu Arg Arg 65 70 75 80
- Val Leu His Pro Ser Pro Val Cys Met Gly Val Ser Cys Leu Cys Gln 85 90 95
- Lys Asn Glu Asp Glu Cys Ala Val Cys Arg Asp Gly Gly Glu Leu Ile 100 105 110
- Cys Cys Asp Gly Cys Pro Arg Ala Phe His Leu Ala Cys Leu Ser Pro
- Pro Leu Arg Glu Ile Pro Ser Gly Thr Trp Arg Cys Ser Ser Cys Leu 130 135 140
- Gln Ala Thr Val Gln Glu Val Gln Pro Arg Ala Glu Glu Pro Arg Pro 145 150 155 160
- Gln Glu Pro Pro Val Glu Thr Pro Leu Pro Pro Gly Leu Arg Ser Ala 165 170 175
- Gly Glu Glu Pro Arg Cys Gln Gly Trp Thr Pro Arg Pro Cys Thr Pro 180 185 190
- Tyr Cys Val Trp Val Leu Arg Val Ser Arg Thr Trp Leu Leu Val Arg 195 200 205
- Val Ala Gly Cys Ala Glu Met Val Arg Thr Cys Cys Gly Val Leu Thr 210 215 220
- Ala Pro Leu Pro Ser Thr Gly Ala Ala Thr Ser Gln Pro Ala Pro Pro 225 230 230 235
- Gly Pro Gly Arg Ala Cys Ala Ala Asp Pro Ala Gln Glu Thr * 245 250 255

#### (2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GATGACACTG CCAGTCACGA

(2) INFORMATION FOR SEQ ID NO: 8:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 22 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:	
GTTCCCGAGT GGAAGGCGCT GC	22
(2) INFORMATION FOR SEQ ID NO: 9:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 20 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:	
AGGGGACAGG CAGGCCAGGT	20
(2) INFORMATION FOR SEQ ID NO: 10:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 24 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:	
GAGTTCAGGT ACCCAGAGAT GCTG	24
(2) INFORMATION FOR SEQ ID NO: 11:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 20 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:	
CTCGCTCAGA AGGGACTCCA	20

(2) INFORMATION FOR SEQ ID NO: 12:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 23 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:	
GGATTCAGAC CATGTCAGCT TCA	23
(2) INFORMATION FOR SEQ ID NO: 13:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 21 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:	
GTGCTGTTCA AGGACTACAA C	21
(2) INFORMATION FOR SEQ ID NO: 14:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 21 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:	
TGGATGAGGA TCCCCTCCAC G	21
(2) INFORMATION FOR SEQ ID NO: 15:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 27 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:	
CCATCCTAAT ACGACTCACT ATAGGGC	2

(2) INFORMATION FOR SEQ ID NO: 16:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 20 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1	.6:
TGCAGGCTGT GGGAACTCCA	20
(2) INFORMATION FOR SEQ ID NO: 17:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 22 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1	.7:
AGAAAAAGAG CTGTACCCTG TG	22
(2) INFORMATION FOR SEQ ID NO: 18:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:         <ul> <li>(A) LENGTH: 22 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul> </li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1	.8:
TGCAAGGAAG AGGGGCGTCA GC	22
(2) INFORMATION FOR SEQ ID NO: 19:	
<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 21 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1	19:
TCCACCACAA GCCGAGGAGA T	21

(2) INFORM	MATION FOR SEQ ID NO: 20:	
(i) S	SEQUENCE CHARACTERISTICS:  (A) LENGTH: 21 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) S	SEQUENCE DESCRIPTION: SEQ ID NO: 20:	
ACGGGCTCCT C	AAACACCAC T	21
(2) INFORM	MATION FOR SEQ ID NO: 21:	
(i) S	SEQUENCE CHARACTERISTICS:  (A) LENGTH: 24 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) S	SEQUENCE DESCRIPTION: SEQ ID NO: 21:	
TGGAGATGGG C	AGGCCGCAG GCTG	24
(2) INFORM	MATION FOR SEQ ID NO: 22:	
(i) S	SEQUENCE CHARACTERISTICS:  (A) LENGTH: 24 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi) S	SEQUENCE DESCRIPTION: SEQ ID NO: 22:	
CAGTCCAGCT G	GGCTGAGCA GGTG	24
(2) INFORM	MATION FOR SEQ ID NO: 23:	
(i) S	SEQUENCE CHARACTERISTICS:  (A) LENGTH: 24 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 23:	
GCGGCTCCAA G	BAAGTGCATC CAGG	24

- (2) INFORMATION FOR SEQ ID NO: 24:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 24 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

CTCCACCCTG CAAGGAAGAG GGGC

24

- (2) INFORMATION FOR SEQ ID NO: 25:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 15 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS:
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Thr Leu His Leu Lys Glu Lys Glu Gly Cys Pro Gln Ala Phe His
1 5 10 15

- (2) INFORMATION FOR SEQ ID NO: 26:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 15 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS:
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Gly Lys Asn Lys Ala Arg Ser Ser Ser Gly Pro Lys Pro Leu Val 1 5 10 15

- (2) INFORMATION FOR SEQ ID NO: 27:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 24 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

#### ATGGCGACGG ACGCGGCGCT ACGC

- (2) INFORMATION FOR SEQ ID NO: 28:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 24 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

#### CCTGGATGTA CTTCTTGGAG CCGC

- (2) INFORMATION FOR SEQ ID NO: 29:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 24 base pairs
      - (B) TYPE: nucleic acid
      - (C) STRANDEDNESS: single
      - (D) TOPOLOGY: linear
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

#### GAGCCCGAGG GGCCGTGGAG GGGA

- (2) INFORMATION FOR SEQ ID NO: 30:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 24 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

#### GGCTGCACCT CCTGGACTGT TGCC

- (2) INFORMATION FOR SEQ ID NO: 31:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 24 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

#### GATCCTGCTC AGGAGACGTG ACCC

- (2) INFORMATION FOR SEQ ID NO: 32:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 24 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

#### CACCAGGCAA GGAGAGGCTC CCGG

- (2) INFORMATION FOR SEQ ID NO: 33:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 20 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

#### CCACCCATG GCGACGGACG

- (2) INFORMATION FOR SEQ ID NO: 34:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 29 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

#### GGAATTCGGA GGGGAAGGGG GCCGCCGGA

- (2) INFORMATION FOR SEQ ID NO: 35:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 24 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

GGACTGAGGA AGGAGGTGTC CTTC

- 2) INFORMATION FOR SEQ ID NO: 36:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 20 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS:
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Asp Gly Ile Leu Gln Trp Ala Ile Gln Ser Met Ala Arg Pro Ala Ala Pro Phe Pro Ser 1 5 10 15 20



10

15

20

25

30

35

#### Claims

- 1. An isolated DNA sequence characterized by comprising the sequence id. no. 1 or a functional fragment or variant thereof encoding a protein having the same functional activity, or an functionally equivalent isolated DNA sequence hybridizable thereto.
- 2. An isolated DNA sequence according to claim 1, characterized in that it is associated with diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 3. An isolated DNA-sequence according to claim 1 or 2, characterized in that it includes a gene defect responsible for APECED.
- 4. A DNA sequence according to claim 1, characterized by having the sequence according to sequence id. no 1 or a functional fragment thereof having the sequence according to sequence id. no 3 or sequence id. no 5.
- 5. A protein characterized by comprising the amino acid sequence id. no. 2 or a functional fragment or variant thereof having the same functional properties.
- 6. A protein according to claim 5, characterized in that it is associated diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 7. A protein according to claim 5 or 6, characterized by having the amino acid sequence id. no. 2, or a functional fragment thereof having the sequence according to sequence id. no. 4, or a functional fragment thereof having the sequence according to sequence id. no 6.
- 8. A protein according to any of claims 5 to 7, characterized by having distinct structural motifs, including the PHD finger motif (PHD), the LXXLL motif (L), proline-rich region (PRR), and cystein-rich region (CRR).
- 9. A method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, characterized by detecting in a biological specimen the presence of a DNA sequence comprising the sequence id. no. 1 or a functional fragment or variant thereof encoding a protein having the same functional activity, or a functionally equivalent isolated DNA-sequence hybridizable thereto.

15

20


25


30


- 10. A method according to claim 9, characterized in that the DNA sequence is associated with APECED.
- 11. A method according to claim 9 or 10, characterized in that the DNA sequence includes a gene defect responsible for APECED.
- 12. A method according to claim 11, characterized in that the gene defect to be detected includes a "C" to "T" transition resulting in the "Arg" to "Stop" nonsense mutation at amino acid position 257 and/or a "A" to "G" transversion resulting in the "Lys" to "Glu" missense mutation at amino acid position 42.
- 13. A method according to any one of claims 9 to 12, characterized in that DNA techniques are used for the detection.
- 14. A method according to any one of claims 9 to 13, characterized in that the detection takes advantage of Taql or another enzyme cleaving at recognition site 5'-TCGA-3' digestion.
- 15. A method according to any one of claims 9 to 14, characterized in that the disease is autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 16. A method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, characterized by detecting in a biological specimen the presence or the absence of a protein comprising the sequence id. no. 2, or a functional fragment thereof having the sequence according to sequence id. no. 4, or a functional fragment thereof having the sequence according to sequence id. no. 6.
- 17. A method according to claim 16, characterized in that the protein is associated with APECED.
- 18. A method according to claim 16 or 17, characterized in that the disease is autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 19. The use of the DNA sequence according to any one of claims 1 to 4 in the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).

- 20. The use of the protein according to any one of claims 5 to 7 in the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 21. The use of the DNA sequence according to any one of claims 1 to 4 for the preparation of a medicament useful in a gene therapy method of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 22. The use of the DNA sequence according to any one of claims 1 to 4 in the treatment of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 23. Reagents reacting with the DNA sequence according to any one of claims 1 to 4 or the protein of any one of the claims 5 to 8 or with reagents reacting therewith.
- 24. Reagents according to claim 23, characterized in that they are antibodies.


1/10







3/10






FIG. 3

4/10





FIG. 4


340 475 414 493 832	
CAVCRDGGELICCDGCPRAFHLACLSPPLREIPSGTWRCSSC.GGTDVLR.TH.AAWR.HF.AGTSR.GTGLREQQI.LTY.MVD.DMEKA.E.K.S.PHRKTSSY.IHNPN.E.L.PRRKVS.YV.T.TNFE.I.TF.	
.: 299 .: 434 .: 373 .: 452	Sus
AIR-1: 299 AIR-1: 434 Mi-2: 373 Mi-2: 452	consensus


FIG. 8

6/10










### 9/10



10/10




FIG.

COMBINED DECLARATION AND POWER OF  (ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEM  CONTINUATION OR C-I-P)  As a below named inventor, I hereby declare that:  TYPE OF DECLARATION  This declaration is of the following type:  (check one applicable item below)	PATENT
(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEM CONTINUATION OR C-I-P)  As a below named inventor, I hereby declare that:  TYPE OF DECLARATION  This declaration is of the following type:  (check one applicable item below)	
As a below named inventor, I hereby declare that:  TYPE OF DECLARATION  This declaration is of the following type:  (check one applicable item below)	ATTORNEY
TYPE OF DECLARATION  This declaration is of the following type:  (check one applicable item below)	ENTAL, DIVISIONAL
This declaration is of the following type:  (check one applicable item below)	
(check one applicable item below)	
onginal.	
design.	
supplemental.	
NOTE If the declaration is for an International Application being filed as continuation-in-part application, do not check next item; check appropriate the continuation of the continuatio	
🗵 national stage of PCT.	
NOTE If one of the following 3 items apply, then complete and also attach AD CONTINUATION OR C-I-P	DED PAGES FOR DIVISIONAL.
divisional.	
continuation.	
continuation-in-part (C-I-P).	
INVENTORSHIP IDENTIFICATION	l
WARNING: If the inventors are each not the inventors of all the claims, an extended the ownership of all the claims at the time the last claimed invention (	
My residence, post office address and citizenship are as stated I believe that I am the original, first and sole inventor (if only one an original, first and joint inventor (if plural names are listed belothat is claimed, and for which a patent is sought on the invention	e name is listed below) or ow) of the subject matter
TITLE OF INVENTION	
Novel gene defective in apeced and its use	

(Declaration and Power of Attorney [1-1]-page 1 of 6)



#### SPECIFICATION IDENTIFICATION

the	specification	of	which.
-----	---------------	----	--------

(complete (a), (b) or (c))
(a) Is attached hereto.
(b) _ was filed on, as _ Senal No. 0 /
or Express Mail No., as Senal No. not yet known
and was amended on (if applicable).
NOTE Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67
(c) $\overline{X}$ was described and claimed in PCT International Application No. PCT/F198/00749 filed on 23 Sept. 1998 and as
amended under PCT Article 19 on (if any).
ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR
I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.
l acknowledge the duty to disclose information, which is material to patentability as defined in 37. Code of Federal Regulations, § 1.56,
(also check the following items, if desired)
and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and
in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 CFR 1.98.
PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))
I hereby claim foreign priority benefits under Title 35. United States Code, § 119(a)–(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.
(complete (d) or (e))
(d) no such applications have been filed.
(e) 🖄 such applications have been filed as follows.
NOTE Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

(Deciaration and Power of Attorney [1-1]—page 2 of 6)



# PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 USC 119
FI	973762	23 Sept. 1997	X YES NO T
			_ YES NO _
			TYES NO T
			TYES NO T
			☐ YES NO ☐

## CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (34 U.S.C. § 119(e))

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER	FILING DATE	
/		
/		
/		

## CLAIM FOR BENEFIT OF EARLIER US/PCT APPLICATION(S) UNDER 35 U.S.C. 120

$\equiv$	The claim for the benefit of any such applications are set forth in the
	attached ADDED PAGES TO COMBINED DECLARATION AND POWER OF
	ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN
	PART (C-I-P) APPLICATION.

(Declaration and Power of Attorney [1-1]-page 3 of 6)

	(6 MONTHS FOR DESIGN) PRIO	R TO THIS U.S. APPLICATION
NOTE.	the basis for this application entering the United divisional, or continuation-in-part, then also co	in the filing date of this application is a PCT filing forming and States as (1) the national stage, or (2) a continuation, implete ADDED PAGES TO COMBINED DECLARATION L. CONTINUATION OR C-I-P APPLICATION for benefit 35 U.S.C. § 120.
	POWER OF	ATTORNEY
	eby appoint the following attomey(s) ansact all business in the Patent and T	
	(list name and reg	istration number)
PAUL B WEST. 18947 JOSEPH H HANDELMAN. 26179 JOHN RICHARDS. 31053 JOHN J CHRYSTAL. 26360 RICHARD J STREIT. 25365 ALAN K ROBERTS. 17277 S. DELVALLE GOLDSMITH, 14383  (check the following it		on and power of attorney, is the authorization
	of the above-named attorney(s) representative(s)	to accept and follow instructions from my
SEND	CORRESPONDENCE TO	DIRECT TELEPHONE CALLS TO. (Name and telephone number)
	ADAS & PARRY S WEST 61ST STREET JEW YORK, NEW YORK 10023	(212)708-1930

#### **DECLARATION**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(Declaration and Power of Attorney [1-1]—page 4 of 6)



(cneck proper boxles) for any of the following added page(s) that form a part of this declaration)

$\boxtimes$	Signature for fourth and subsequent joint inventors. Number of pages added 2
Ξ	Signature by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor. Number of pages added
	• • •
=	Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added
=	Added page for signature by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1 47)
	• • •
=	Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.
	Number of pages added
Ξ	Authorization of attorney(s) to accept and follow instructions from representative.
	• • •
t	(if no further pages form a part of this Declaration, then end this Declaration with this page and check the following item)
	This declaration ends with this page.

(Deciaration and Power of Attorney [1-1]-page 6 of 6)

=

#### SIGNATURE(S)

NOTE: Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other Full name of sole or first inventor 1-00 Krohn (GIVEN NAME) MIDDLE MITTAL FAMILY (OR LAST NAME) Inventor's signature Finland Country of Citizenship Post Office Address Full name of second joint inventor, if any Heino Maarıt GIVEN NAME (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME) inventor's signature. Date 2,3, 2000 Finland Country of Citizenship Post Office Address Full name of third joint inventor, if any Pärt Peterson FAMILY (OR LAST NAME) GIVEN NAME inventor's signature Date 2,3, 2000 Estonia Country of Citizenship Residence Kaskit TMPERE

(Deciaration and Power of Attorney [1-1]-page 5 of 6)

-7

Attorney's	Docket	Mo	U 012653-9
~	-vever	NV.	

# ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS

Full name of fourth joint	inventor, if any	
Hamıs <u>h</u>	5_,	Scott
GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
Inventor's signature	Humah Just	
Date	Country of Citizenship	Australia
Residence	KINGGISHER CARGENS	AUX
Post Office Address	RUNSVICK USTST	
- VIC PORIA	3057 AUSTALIA	
Full name of fifth joint inv	ventor if any	
Stylianos	const, if any	Antonarakıs
GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
Inventor's signature		
	Country of Citizenship _	US/Greece
Residence		
Post Office Address		
End page of such court		
Full name of sixth joint in	ventor, it any	1 - 1 1 .
Maria GIVEN NAME	MIDDLE INITIAL OR NAME	Lalıoti
· · · · · · · · · · · · · · · · · ·	Lativity	FAMILY (OR LAST NAME)
Inventor's signature	9 1 1	
Date 10-10-00	Country of Citizenship _	
Residence	79 STOCKDALE	PLACE
Post Office Address		MINGHAM
	B15 3xH U	<u> </u>

Attomovis	Dooket	No	U 012653-9
wirouseh -	DOCKEL	HU.	

## ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS

	Full name of fourth joint inv	ventor, if any	C 13
1-00	Hamish GIVEN NAME	MIDDLE INITIAL OR NAME	Scott  FAMILY FOR LAST NAME
-1	• • • • • • • • • • • • • • • • • • • •		PAMILY (OR DAS) NAME
	Inventor's signature		Australia
	Date	Country of Citizenship _	Macraria
	Residence		
	Post Office Address		
			-
	Full name of fifth joint invei	ntor, if any	
10	Stylianos		Antonarakıs
, 0	GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
	Inventor's signature	C. 7 30 10 10 10 10 10 1	10.70
	Date 29 Fep UV	Country of Citizenship	US/Greece
	Residence 28 BINA	dos 1440sophes	<u> </u>
	Post Office Address 12	05 GENERA	
		WIZZERMAN	
	Full name of sixth joint inve	entor, if any	
/ 6 ⁰	Maria	<u></u>	<u>Lalıotı</u>
W.	GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
	Inventor's signature	Copway	
	Date18-10-00	Country of Citizenship _	GREE CE
	Residence	9 STOCKDALE P	L. EDGBASTON
	Dest Office Address	BIRMINICHTAN UK	BIS 3XH

#### SIGNATURE(S)

NOTE. Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents. Full name of sole or first inventor Krohn (GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY FOR LAST NAME Inventor's signature ____ Date _____ Country of Citizenship ___ Finland Residence ____ Post Office Address _____ Full name of second joint inventor, if any Maarit Heino (GIVEN NAME) (MIDDLE INITIAL OR NAME) FAMILY (OR LAST NAME) Inventor's signature _____ Date _____ Country of Citizenship _ Finland Residence _____ Post Office Address _____ Full name of third joint inventor, if any Pärt Peterson (GIVEN NAME) IMIDOLE INITIAL OR NAME) FAMILY (OR LAST NAME) inventor's signature ___ Date _____ Country of Citizenship _ Estonia Residence __ Post Office Address ___

(Deciaration and Power of Attorney [1-1]-page 5 of 6)

## (check proper boxles) for any of the following added page(s) that form a part of this declaration)

X	Signature for fourth and subsequent joint inventors. Number of pages added _2
	• • •
=	Signature by administrator(tnx), executor(tnx) or legal representative for deceased or incapacitated inventor. Number of pages added
	• • •
Ξ	Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added
=	Added page for signature by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1.47)
=	Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.
	Number of pages added
=	Authorization of attorney(s) to accept and follow instructions from representative.
	(if no further pages form a part of this Declaration, then end this Declaration with this page and check the following item)
	This declaration ends with this page.

(Declaration and Power of Attorney [1-1]-page 6 of 6)

Attorney's Docket N	· · · · · · · · · · · · · · · · · · ·	
	-	
ADDED PAGE	TO COMBINED DECLARATION	AND POWER OF
ATTORNEY FOR SIC	SNATURE BY FOURTH AND SU	BSEQUENT INVENTORS
Full name of 7th joint	inventor, if any	
Nobuyoshi		Shimızu
GIVEN NAME	MIDDLE INITIAL OR NAME .	FAMILY (OR LAST NAME)
Inventor's signature		
Date	Country of Citizenship	Japan
		_
. 03. 011106 7001633		
m at a second of the second		-
Full name of 8thjoint in	iventor, if any	17d = l=
Jun GIVEN NAME	MIDDLE INITIAL OR NAME	Kudoh
		FAMILY (OR LAST NAME)
		-
Date	Country of Citizenship	Japan
Residence		
Post Office Address		
Full name of 9th joint i	nventor, if any	
GIVEN NAME	MIDDLE INTIAL OR NAME	FAMILY (OR LAST NAME)

MIDDLE INITIAL OR NAME

_____ Country of Citizenship __

Inventor's signature ___

Residence _____ Post Office Address ___

Date ____

FAMILY (OR LAST NAME)

Attorney's Decket No	U 012653-9	PATENT
COMBINED DEC	LARATION AND PO	WER OF ATTORNEY
(ORIGINAL, DESIGN, NAT	IONAL STAGE OF PCT, CONTINUATION OR C	SUPPLEMENTAL DIVISIONAL -1-P)
As a below named inventor	, I hereby declare that:	
	TYPE OF DECLARAT	TION
This declaration is of the follo	wing type:	
(cr	neck one applicable item	below)
onginal.		
design.		
supplemental.		
		peing filed as a divisional, continuation or check appropriate one of last three items.
national stage of P	CT.	
NOTE If one of the following 3 its CONTINUATION OR C-I-P		iso attach ADDED PAGES FOR DIVISIONAL,
divisional.		
continuation.		
continuation-in-par	t (C-I-P).	
INV	ENTORSHIP IDENTIF	FICATION
		claims, an explanation of the facts, including ned invention was made, should be submitted.
I believe that I am the original	i, first and sole inventor entor (if plural names are	as stated below, next to my name. (if only one name is listed below) or listed below) of the subject matter the invention entitled:
	TITLE OF INVENT	ION
Novel gene defective i	n apeced and its u	Se ·

(Declaration and Power of Attorney [1-1]--page 1 of 6)

#### SPECIFICATION IDENTIFICATION

the	Speci	fication	of	which

	ı	complete	(a). I	b	) or	(c)	)
--	---	----------	--------	---	------	-----	---

<b>(a)</b>	_	is attached hereto.		
<b>(b</b> )	Ξ	was filed on or _ Express Mail No., as Serial and was amended on	No. not yet known	
NOT	r a a	Amenaments filed after the onginal papers on accorded a filing date by being referred to are those filed with the application papers of amendments claiming matter not encompass TCFR 1.67	in the declaration. Accordingly, to or, in the case of a supplement	he amendments involved al declaration, are those
(C)	$\overline{\mathbf{x}}$	was described and claimed PCT/F198/00749 file	ed on <u>23 Sept. 1998</u>	and as
		amended under PCT Article 19 d	n	(if any).
AC	KN	OWLEDGEMENT OF REVIEW	OF PAPERS AND DUT	Y OF CANDOR
speci	ficat ckno	by state that I have reviewed and un tion, including the claims, as amen owledge the duty to disclose infor in 37. Code of Federal Regulations,	ded by any amendment remails material	eferred to above.
denne	<b>30</b> 11	n 37, Code of Federal Regulations,	9 1.50,	
		(also check the follow	wing items, if desired)	•
	Ξ	and which is material to the exam- where there is a substantial likeliho it important in deciding whether and	ood that a reasonable Exam	niner would consider
		in compliance with this duty statement, in accordance wi		ormation disclosure

**PRIORITY CLAIM** (35 U.S.C. § 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)–(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) I no such applications have been filed.
- (e) 🖄 such applications have been filed as follows.
- NOTE Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

(Declaration and Power of Attorney [1-1]-page 2 of 6)



## PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 USC 119
FI	973762	23 Sept. 1997	☑ YES NO □
			TYES NO T
			TYES NO T
			☐ YES NO ☐
			☐ YES NO ☐

## CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (34 U.S.C. § 119(e))

I hereby claim the benefit under Title 35. United States Code, § 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER	FILING DATE

### CLAIM FOR BENEFIT OF EARLIER US/PCT APPLICATION(S) UNDER 35 U.S.C. 120

_	The claim for the benefit of any such applications are set forth in th	е
	attached ADDED PAGES TO COMBINED DECLARATION AND POWER O	F
	ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-I	N
	PART (C-I-P) APPLICATION.	

(Deciaration and Power of Attorney [1-1]-page 3 of 6)

ÁLL F	FOREIGN APPLICATION(S), IF A (6 MONTHS FOR DESIGN) PRIO	NY, FILED MORE THAN 12 MONTHS R TO THIS U.S. APPLICATION
NOTE.	the basis for this application entering the United divisional, or continuation-in-part, then also co	in the filing date of this application is a PCT filing forming of States as (1) the national stage, or (2) a continuation, implete ADDED PAGES TO COMBINED DECLARATION L, CONTINUATION OR C-I-P APPLICATION for benefit 35 U.S.C. § 120.
	POWER OF	ATTORNEY
	eby appoint the following attomey(s) and I have all business in the Patent and I	and/or agent(s) to prosecute this application rademark Office connected therewith.
	(list name and reg	istration number)
PA	UL B WEST, 18947	PETER D. GALLOWAY, 27885
JOSEPH H. HANDELMAN, 26179		IAIN C. BAILLIE, 24090
JOHN RICHARDS, 31053		THOMAS F. PETERSON, 24790
JOHN J CHRYSTAL, 26360		RICHARD P. BERG, 28145
	CHARD J STREIT, 25765	JULIAN H. COHEN, 20302
	LAN K ROBERTS, 17777	WILLIAM R. EVANS, 25858
S.	DELVALLE GOLDSMITH, 14383	JANET I. CORD, 33778
	Charles Aller & Warring	CLIFFORD J. MASS, 30086
	(check the following	g item, if applicable)
	Attached, as part of this declarate of the above-named attorney(s) representative(s)	on and power of attorney, is the authorization to accept and follow instructions from my
SEND	CORRESPONDENCE TO	DIRECT TELEPHONE CALLS TO. (Name and telephone number)
2	ADAS & PARRY 26 WEST 61ST STREET JEW YORK, NEW YORK 10023	(212)708-1930

#### DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(Deciaration and Power of Attorney [1-1]-page 4 of 6)



Attorney's Decket No. U 012653-9	PATENT
COMBINED DECLARATION AND POWER OF ATTOR	NEY
(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, CONTINUATION OR C-I-P)	DIVISIONAL
As a below named inventor, I hereby declare that:	
TYPE OF DECLARATION	
This declaration is of the following type:	
(check one applicable item below)	
Conginal.	
design.	
supplemental.	
NOTE. If the declaration is for an International Application being filed as a division continuation-in-part application, do not check next item; check appropriate one	
🗵 national stage of PCT.	
NOTE If one of the following 3 items apply, then complete and also attach ADDED PAGE CONTINUATION OR C-I-P	ES FOR DIVISIONAL,
divisional.	
continuation.	
continuation-in-part (C-I-P).	
INVENTORSHIP IDENTIFICATION	
WARNING: If the inventors are each not the inventors of all the claims, an explanation of the ownership of all the claims at the time the last claimed invention was made,	•
My residence, post office address and citizenship are as stated below, in believe that I am the original, first and sole inventor (if only one name is an original, first and joint inventor (if plural names are listed below) of that is claimed, and for which a patent is sought on the invention entitle	s <i>listed below)</i> or ne subject matter
TITLE OF INVENTION	
Novel gene defective in apeced and its use	
	·

(Deciaration and Power of Attorney [1-1]-page 1 of 6)

#### SPECIFICATION IDENTIFICATION

the	speci	fication	Of.	which:

(complete (a), (b) or (c))
(a) is attached hereto.
(b) was filed on as Senal No. 0 /
or Express Mail No., as Senal No. not yet knownand was amended on(if applicable).
NOTE Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67
(c) x was described and claimed in PCT International Application No.
PCT/F198/00749 filed on 23 Sept. 1998 and as amended under PCT Article 19 on (if any).
ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR
I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.
I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, § 1.56,
(also check the following items, if desired)
and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and
in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 CFR 1.98.
PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))
I hereby claim foreign priority benefits under Title 35. United States Code, § 119(a)–(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.
(complete (d) or (e))
(d) _ no such applications have been filed.
(e) 🖄 such applications have been filed as follows.
NOTE Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

(Deciaration and Power of Attorney [1-1]-page 2 of 6)



# PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 USC 119
FI	973762	23 Sept. 1997	X YES NO
			_ YES NO _
			TYES NO T
			☐ YES NO ☐
			☐ YES NO ☐

## CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (34 U.S.C. § 119(e))

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER	FILING DATE
/	
/	

## CLAIM FOR BENEFIT OF EARLIER US/PCT APPLICATION(S) UNDER 35 U.S.C. 120

_	The claim for the benefit of any such applications are set forth in th	ıе
	attached ADDED PAGES TO COMBINED DECLARATION AND POWER O	
	ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-I	N
	PART (C-I-P) APPLICATION.	

(Deciaration and Power of Attorney [1-1]-page 3 of 6)

	FOREIGN APPLICATION(S), IF AN (6 MONTHS FOR DESIGN) PRIO	YY, FILED MORE THAN 12 MONTHS R TO THIS U.S. APPLICATION
NOTE.	the basis for this application entering the United divisional, or continuation-in-part, then also con	in the filing date of this application is a PCT filing forming of States as (1) the national stage, or (2) a continuation, inplete ADDED PAGES TO COMBINED DECLARATION CONTINUATION OR C-I-P APPLICATION for benefit 5 U.S.C. § 120.
	POWER OF A	TTORNEY
	eby appoint the following attomey(s) and neart all business in the Patent and Ti	nd/or agent(s) to prosecute this application rademark Office connected therewith.
	(list name and regi	4
	UL B WEST. 18947	PETER D. GALLOWAY, 27885
	SEPH H. HANDELMAN, 26179	IAIN C. BAILLIE. 24090
	HN RICHARDS. 31053	THOMAS F. PETERSON, 24790
	HN J CHRYSTAL. 26360—	RICHARD P. BERG. 28145
	CHARD J STREIT 25765	JULIAN H. COHEN <u>. 20302</u> WILLIAM R. EVANS, <u>25858</u>
	AN K ROBERTS, 17777 DELVALLE GOLDSMITH, 14383	JANET I. CORD, 33778
3.	DELVALLE GOLDSMITH, 14383	CLIFFORD J. MASS, 30086
	(check the following	in the same of the
ļ	<ul> <li>Attached, as part of this declaration of the above-named attorney(s) representative(s)</li> </ul>	on and power of attorney, is the authorization to accept and follow instructions from my
SEND (	CORRESPONDENCE TO	DIRECT TELEPHONE CALLS TO. (Name and telephone number)
L	ADAS & PARRY	
2	& WEST 61ST STREET	(212)708-1930
4	EW YORK, NEW YORK 10023	<del>,</del> /

#### DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(Declaration and Power of Attorney [1-1]—page 4 of 6)



#### SIGNATURE(S)

NOTE Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents. Full name of sole or first inventor Kai Krohn (MIDDLE INITIAL OR NAME) (GIVEN NAME) FAMILY FOR LAST NAME Inventor's signature ____ Finland _____ Country of Citizenship ___ Residence _____ Post Office Address _____ Full name of second joint inventor, if any Heino Maarit (MIDDLE INITIAL OR NAME) (GIVEN NAME) FAMILY (OR LAST NAME) Inventor's signature ___ Finland Date _____ Country of Citizenship _ Residence ___ Post Office Address __ Full name of third joint inventor, if any Peterson Pärt MIDDLE INITIAL OR HAME) FAMILY (OR LAST NAME) (GIVEN NAME) Inventor's signature ____ Estonia Date _____ Country of Citizenship __ Residence _____ Post Office Address ____

(Decisization and Power of Attorney [1-1]-page 5 of 6)

## (check proper box(es) for any of the following added page(s) that form a part of this declaration)

X	Signature for fourth and subsequent joint inventors. Number of pages added 2
Ξ	Signature by administrator(tnx), executor(tnx) or legal representative for deceased or incapacitated inventor. Number of pages added
	• • •
=	Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added
	• • •
=	Added page for signature by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1.47)
	• • •
_	Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.
	Number of pages added
	• • •
=	Authorization of attorney(s) to accept and follow instructions from representative.
	· · ·
;	(if no further pages form a part of this Declaration, then end this Declaration with this page and check the following item)
	This declaration ends with this page.

(Declaration and Power of Attorney [1-1]-page 6 of 6)

Attorney's Docket No		
		-
ADDED BACE	TO COMBINED DECLARATION	I AND BOWED OF
	NATURE BY FOURTH AND SU	
Full name of fourth joint	inventor, if any	Scott
Hamish Given name	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
		·
Date	Country of Citizenship	Australia
Date	Country of Chilesising	
Post Office Address		
Full name of fifth joint in	ventor, if any	
Stylianos		Antonarakıs
GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
inventor's signature		.c./n
Date	Country of Citizenship _U	5/Greece
Post Office Address		
Full name of sixth joint ii	number if any	
-	iventor, ir arry	Lalioti
Maria GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
Inventor's signature		
	Country of Citizenship	
Residence		
Doet Office Address		

	Attorney's Docket No.		
	ADDED PAGE TO COME ATTORNEY FOR SIGNATURE		
	Full name of 7th joint inventor, if	any	
ic	•		Shimizu
<b>,</b> ,		ODLE INITIAL OR NAME .	FAMILY (OR LAST NA
	Inventor's signature		
	Date	Country of Citizenship	Japan
	Residence		
	Post Office Address		
			-
~	Full name of 8thjoint inventor, if a	·	Kudoh
$G_{\mathbf{j}}$	Jun Muse Mu	DOLE INITIAL OR NAME	FAMILY FOR LAST NA
	Inventor's signature		
	Date		Japan
	Residence		
	Post Office Address		
	Post Office Address		
	Full name of 9th joint inventor, if	any	-
	CIVEN NAME M	DOLE INITIAL OR NAME	FAMILY (OR LAST NA

Inventor's signature _____

Residence ______
Post Office Address __

Date _____ Country of Citizenship _____

Date _____Residence _

Post Office Address.

5/9 FAX to .
318-3-3131-7050

U 012653-9 1. Attorney's Docket No. ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS Full name of 7th joint inventor, if any <u>Nobuyoshi</u> Shim120 MIDDLE INITIAL OR NAME GIVEN NAME FAMILY WE LAST NAME) Inventor's signature Japan Post Office Address . Full name of 8thjoint inventor, if any Kudoh GIVEN NAME MIDDLE INITIAL OR NAME Inventor's signature Date May 8 Japan Residence _ Post Office Address. Full name of 9th joint inventor, if any MIDDLE INITIAL OR NAME FAMILY (OR LAST NAME) GIVEN NAME Inventor's signature _

(Added Page to Combined Declaration and Power of Attorney for Signature by Fourth and Subsequent Inventors [1-2])

____ Country of Citizenship _